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1 Abstract 
SUMOylation (Small Ubiquitin-related MOdifier) is a post-translational protein 
modification that can alter the sub-cellular localization, the activity or the 
interaction partners of proteins. Thus, this reversible modification has been 
associated with many important cellular processes and the number of newly 
identified SUMO substrates is steadily increasing. Several chromatin modifying 
enzymes are modified by SUMO – many of which are responsible to set and to 
maintain repressive Histone and DNA methylation characteristic for silent 
heterochromatin. The essential tri-enzymatic SUMO cascade comprises a single 
E1, a single E2 and several E3 enzymes. The E2 enzyme Ubc9 was found to be 
deregulated in cancer and is associated with metastasis, tumor cell invasion and 
resistance to chemotherapy. This study aims to investigate the consequences of 
Ubc9 deregulation on chromatin in NIH 3T3 mouse fibroblasts. Therefore, the 
Histone lysine methylation at H3K9 and H4K20, which are characteristic for 
pericentromeric heterochromatic regions, were investigated. Thereby, Ubc9-
siRNA treatments of cells lead to growth arrest and an increase in H4K20 
methylation. In contrast to that, no change was observed for the other prominent 
repressive histone mark, the H3K9 tri-methylation. 
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2 Introduction 
2.1 Principle of SUMOylation 
SUMOylation is an essential posttranslational modification related to protein 
ubiquitinylation. Although SUMO and ubiquitin share a similar structural fold their 
sequence homology is only 18%1. Ubiquitinylation often functions as signal for 
degradation whereas SUMOylation is involved in diverse cellular functions as 
transcription, chromatin structure, DNA repair, signaling and stability of target 
proteins 2, 3, 4, 5. This is due to the change of this posttranslational modification in 
binding affinities with proteins, DNA or RNA6, 7. Thereby SUMO can even 
compete with ubquitin for the lysine residue and thus contributes to target 
stability8. SUMOylation is highly conserved throughout evolution, but was not 
found in eubacteria and archea. Eukaryotes have varying numbers of SUMO 
paralogues ranging from one protein in yeast to four SUMO variants in 
mammals9.  
SUMO is an 11kDa protein and its conjugation to substrates (sumoylation) is 
performed by an energy dependent hierarchical tri- enzyme cascade (Figure 1). 
In the first ATP consuming reaction SUMO gets activated and forms a thioester 
bond with the E1 activating enzyme which is the heterodimer between SAE1 and 
SAE2 (Aos1 and Uba2 in yeast)10, 11. Subsequently, SUMO is transferred from 
the E1 to the E2 conjugating enzyme Ubc9 again resulting in a thioester bond12, 
13. Ubc9 can either directly transfer SUMO to the substrate or - more commonly – 
needs the help of an E3 ligating enzyme for efficient substrate modification14, 15. 
This results in an isopeptide bond between the C-terminal glycine of SUMO and 
the ε-amino group of the target lysine16 . Such lysines are often part of the SUMO 
consensus motif ψKXE/D with Ψ as a hydrophobic amino acid and X as any 
residue17, 18.  
SUMO can also regulate proteins functions in a non-covalent manner by binding 
to a specific SUMO interactions motif (SIM) in a substrate. Such motifs are short 
hydrophobic regions in a β-sheet structure often flanked by acidic amino acids 
which interact with the β-sheet in SUMO19, 20, 21. SUMOylation is a reversible 
process and different SUMO specific proteases are identified. The most 
prominent representatives are the six members of the Senp family (Senp family 
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members 1-3 and 5-7)22, 23 but very recently two novel classes of SUMO 
proteases were described, DeSI-1 and Uspl124. SUMO proteases can carry out 
different functions: isopeptide cleavage leading to dissociation of SUMO from its 
substrate, SUMO processing for maturation of the SUMO precursor or SUMO 
chain editing (Figure 3). Also preferences for either SUMO1 or SUMO 2/3 are 
described for specific Senp family members25, 26, 27, 28. 
2.2 Ubc9 deregulation  
SUMOylation is mainly regulated at the level of E3 ligases and isopeptidases 
since these enzymes ensure substrate specificity. Little is known about regulation 
at the level of the sole E2 enzyme which is essential for SUMO conjugation. 
Regulation at this step of the enzyme cascade is expected to have severe 
consequences on all downstream events, the E3 ligases and substrates.  
Ubc9 is highly conserved and its deletion is lethal in most organism from baker´s 
yeast to mice29, 30. However, deletion of fission yeast homologue, hus5, is viable 
Figure 1: SUMO conjugation to its substrate: After removal of SUMO C-terminal residues 
by SUMOproteases SUMO is activated by the E1 heterodimer Aos1- Uba2 by the expense of 
ATP and forms a thioester bond with the E1 enzyme. SUMO is then transferred to the E2 
enzyme Ubc9 again forming a thioester bond. Finally, the C-terminal glycine forms an 
isopeptide bond with a lysine in the target protein, which is normally assisted by an E3. 
However, there are targets which are SUMOylated directly by Ubc9. SUMOylation is 
reversible and demodification is performed by SUMOspecific proteases. (Adaped from 
Meulmeeser and Melchior 9) 
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although these cells are severely impaired in growth with defects in mitosis 
resulting in chromosome missegregation31, 32. Ubc9-depleted Caenorhabditits 
elegans displays developmental defects comparable to mutations in 
developmental regulators, as for example in Hox genes33. Also in Drosophila 
melanogaster the semushi (semi is the Drosophila SUMO-E2) mutant strain 
suffers from defects in the arterior-posterior patterning during development34. In 
zebrafish, expression of a dominant negative mutant causes widespread 
apoptosis whereas anti-sense mediated Ubc9 knock down showed defects in 
later proliferating tissues such as brain and eyes. More detailed analyses 
indicated that Ubc9 depletion results in a G2/M arrest of the cell cycle and the 
accumulation of polyploid cells 35. Conditional Ubc9 depletion in DT40 chicken 
cells demonstrated chromosomal loss and apoptosis and a subpopulation of 
multinucleated cells. In contrast to other studies in those cells there a G2/M arrest 
was not detected36.  
In mice Ubc9 is essential and Ubc9 deficient mouse embryos die early in 
development after the blastocyte stage. Interestingly, such blastocytes are viable 
for up to two days before undergoing apoptosis. Analysis of these cells indicated 
severe chromosomal defects and major changes in the nuclear architecture of 
the inner cell mass30.  
Interestingly, not only the downregulation of Ubc9 has severe consequences on 
cell homeostasis also its upregulation by ectopic expression promotes cell 
invasion and metastasis. In line, Ubc9 upregulation correlates with different 
human malignancies37. In colon adenocarcinoma and prostate intraepithelial 
neoplasia Ubc9 was found to be elevated compared to normal tissue and Ubc9 
expression increased with progressed disease stages. Luminal and non-luminal 
breast cancer tissue also significantly differed in their levels of Ubc9 expression 
with upregulation in luminal breast cancer tissue. Moreover, hormone (estrogen 
and/or progesterone) receptor-positive breast cancer tissues also showed higher 
Ubc9 levels than hormone receptor-negative tumors38. Furthermore, stable 
expression of a Ubc9 wt or Ubc9 double mutant in breast cancer cells yielded to 
higher tissue invasion as a control vector and accordingly breast cancer cells 
treated with Ubc9-siRNA did not show tissue invasion39. In agreement, clinical 
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responses of breast cancer patients to neoadjuvant chemotherapy were 
compromised by higher Ubc9 expressing tumors40 . 
However, these data clearly demonstrate that Ubc9 deregulation has severe 
consequences on cell homeostasis: Ubc9 upregulation appears to promote 
cancer progression whereas its downregulation results in severe chromosomal 
defects indicating an important role for Ubc9 in the regulation of chromatin 
structure and function. 
2.3 Chromatin and its regulation 
Chromatin describes the complex organization of DNA with proteins which 
achieves the dynamic regulation between DNA compaction and accessibility to 
regulate chromatin functions. In metaphase chromosomes are highly condensed, 
whereas in interphase chromatin can be divided in decondensed euchromatin 
and highly condensed heterochromatin41.  
The basic unit of chromatin is the nucleosome in which 146bp of DNA are 
wrapped around a protein octamer. Such octamers consist of each two of the 
core histones H2A, H2B, H3 and H441, 42. However, the length of linker regions 
between the nucleosomes varies between species and cell type. Consistently, 
the histones associated with linker regions such as histone H1, are also less 
conserved as core histones and regulate nucleosome spacing and compaction43.  
Changes in the highly organized chromatin structure are introduced by various 
mechanisms such as DNA methylation, posttranslational histone modifications, 
chromatin remodelling enzymes which allow the exchange of core histones with 
their variants42. 
DNA methylation at cytosines next to guanines (CpGs) is a covalent DNA 
modification in which a methyl group is added at the 5´position on the pyrimidine 
ring44. The functional consequences of DNA methylation on chromatin include 
transcriptional gene silencing, genome stability, chromatin compaction, 
suppression of homologous recombination between repeats and X chromosome 
inactivation45. Two classes of enzymes responsible for DNA methylation are 
described: the maintenance methyltransferase Dnmt1, and the de novo 
methyltransferases Dnmt3a and Dnmt3b46. DNA methylation together with 
histone methylation leads to gene repression and forms condensed 
heterochromatin for transient (facultative heterochromatin) or stable gene 
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silencing (constitutive heterochromatin)47. Besides DNA methylation, histone 
modifications are key players in regulating chromatin structure and function48.  
The small histones consist of core domains involved in octamer formation and 
unstructured N-terminal tails which are particularly rich in lysine and arginine 
residues42. These tails protrude out of the histone complex making them easily 
accessible for diverse post-translational modifications. Such modifications 
change the charge of the highly basic histones which alters DNA accessibility and 
protein binding affinities to the nucleosome. A large number of enzymes are 
described which regulate addition and removal of methyl groups on lysines and 
arginines, phosphorylation on serines and threonines, and acetylation or 
ubiquitination on lysines, as just to mention the best understood and most studied 
examples42, 48. The consequences of these modifications can be diverse as 
methylation can either be a repressive or an activating mark, depending on the 
position of the modified residue and whether the residue is mono-, di- or 
trimethylated48. In contrast, phosphorylation and acetylation are rather enriched 
at actively transcribed genes in open chromatin49. The term ‘histone code’ refers 
to the combination of all the post-translational modifications that are interpreted 
by specific proteins determining the chromatin status42. The highly dynamic 
chromatin state and the transition from closed to open chromatin is achieved by 
the activity of a variety of such multiprotein chromatin regulatory complexes50. 
One important class are the ATP-dependent chromatin remodelling complexes 
with functions in increasing DNA accessibility, nucleosome sliding and 
dissociation of histones from DNA, a dynamic process required for exchange of 
histone variants51.  
Histone variants are described for different core histones and mark specific 
regions on chromatin. Prominent examples are the histone H3 variant CENP-A 
which is associated with silent centromeric regions or H3.3 often found in actively 
transcribed genes (Figure 2)42, 48, 49. Most variations are known for H2A including 
H2A.X involved in DNA repair, H2A.Z in transcription regulation and macroH2A 
present on the inactive X chromosome of female mammals42,48. 
Page 7 of 82 
 
The methylation of histones is achieved by enzymes being specific for the target 
and/or even for their mono-, di and tri-methylation at a distinct lysine52, 53, 54. 
Thereby, H3K9me3, H4K20me3 and H3K27me3 were found to localize to 
pericentric constitutive heterochromatin. Several enzymes and co-enzymes 
establishing and maintaining condensed and silent chromatin were associated 
with sumoylation55, 56, 57.  
2.4 Sumoylation and chromatin 
Although sumoylation is involved in most biological processes it has distinguished 
functions in the nucleus including intracellular transport, cell cycle progression, 
DNA repair, transcriptional control and chromatin regulation2,3,4. Consistently, 
components of the general transcription machinery58, several transcription factors 
Figure 2: Proteins that establish and maintain heterochromatin: Histone composition changes 
with chromatin condensation: H3.3 is found in open, transcribed regions whereas CENP-A is only 
found in the centromere of the chromosome. Heterochromatin is characterized by H3K9me3, 
H3K27me3 and H4K20me3 which are recognized by specific protein complexes. Su(Var)3-9 sets 
H3K9me3. HP1 binds to H3K9me3 and is in a complex with Su(Var)4-20 for setting of H4K20me3. 
PRC2 sets H3K27me3 which attracts further repressive complexes (eg.: PRC1-Pc2) and 
corepressors (eg.: CtBP) DNA methylation at Cytosines in CpG context aids in gene repression as a 
signal for further repressive complexes (e.g.: MDB-1, not indicated). Arrows indicate the enzymes 
setting the respective tri-methylation.42 
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(e.g. CBP, Smad4, p53,...)8, 59, 60 and their regulators61, 62 are modulated via 
sumoylation. Moreover, also several key regulators of chromatin function are 
substrates for sumoylation. This includes all DNA methylating enzymes Dnmt1, 
Dnmt3a and Dnmt3b63, 64. Also in regard of histone modifications sumoylation has 
a major role. All core histones and some variants are modified with SUMO and 
several enzymes controlling histone acetylation (e.g. HDACs) and methylation 
(e.g. LSD1) are substrates of sumoylation or affected by sumoylation of 
interaction partners65, 66, 67, 68, 69, 70, 71. 
Moreover, enzymes of the SUMO machinery were linked to chromatin regulation 
as a drosophila PIAS E3 ligase mutant was identified as a Su(var)2-10 
(suppressor of position effect variegation 2-10), suggesting that PIAS has an 
important role in heterochromatin formation. Su(var)2-10 locus was reported to 
stabilize chromosome structure and function72. Furthermore, Pc2, a member of 
polycomb proteins which are chromatin factors maintaining developmental gene 
silencing, is described to have SUMO E3 ligase functions73.  
Taken together, several studies identified sumoylation as major regulator of many 
chromatin associated proteins and this modification is often found connected to 
gene silencing and repressed transcription activity. Interestingly, a recent study 
investigated the occupancy of SUMO1 on chromatin and identified it enriched 
upstream of the transcription start sites of many active housekeeping genes 
correlating with the transcription active mark H3K4me274. This finding suggests 
that we are just at the very beginning in understanding the function of SUMO at 
chromatin. 
  
Page 9 of 82 
 
2.5 Aim of the project 
Sumoylation is an essential posttranslational modification. Deregulation of Ubc9, 
one key enzyme for sumoylation has severe consequences: Ubc9 deficiency in 
mice or baker´s yeast is lethal and results in cell cycle arrest and severe 
chromosomal defects and major changes in the nuclear architecture. This is 
consistent with a large number of SUMO substrates involved in chromatin 
regulation. Furthermore, Ubc9 upregulation was found in different types of cancer 
and ectopic expression of Ubc9 promotes cell invasion and metastasis.  
In the proposed thesis I aimed to analyse the consequences of Ubc9 
deregulation on heterochromatin formation. Ubc9 deregulation was aimed to be 
studied by both overexpression as it is found in various cancer cells but also by 
its downregulation. For investigating Ubc9 overexpression a stable, Ubc9 
inducible, NIH3T3 cell line was established. Downregulation was studied by 
siRNA-mediated Ubc9 knock down. Finally, cells were investigated for changes in 
specific heterochromatin associated histone marks by immunoblotting and 
immunofluorescence. 
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Figure 3: Protein density profile of Ubc9 elution after size exclusion 
chromatography on an ÄKTA FPLC system: Ubc9 eluted highly 
concentrated between 289ml and 294ml as one peak. The x-axis represents 
the eluted volume in ml and the y-axis the protein concentration in mAU (milli 
absorbance unit) at 280nm.  
3 Results 
Ubc9 is a key enzyme for sumoylation. Different studies indicate that its 
deregulation has severe consequences on cell homeostasis. Whereas 
downregulation is associated with severe chromosomal aberrations its 
upregulation was found in different types of cancer. To study Ubc9 deregulation 
requires the availability of good anti-Ubc9 antibodies. 
3.1 Purification and Characterization of Ubc9 Antibodies 
To obtain Ubc9 specific antibodies a goat was immunized with recombinant 
human Ubc9 protein. To reduce unspecific background staining and increase 
antibody specificity, affinity purification of the goat serum was performed. This 
requires the purification of recombinant Ubc9 from bacteria and subsequent 
coupling to cyanbromide-activated sepharose. Ubc9 specific antibodies were 
enriched on this Ubc9 coupled sepharose and were then eluted.  
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3.1.1 Purification of recombinant Ubc9 
Ubc9 has the size of 18 kDa and was expressed as untagged protein from the 
pET23a plasmid driven by the IPTG inducible T7 promoter. The plasmid was 
transformed into the bacteria strain BL21 gold and induction was with 1 mM IPTG 
for 4 hours at 37°C. Lyses was done by a freeze/thaw cycle followed by 
sonication on ice. Because of its positive charge, Ubc9 was first enriched by ion 
exchange chromatography on SP sepharose, a strong cation exchange matrix. 
Upon high salt elution, the protein was concentrated and further purified by a 
HiLoad S200 size exclusion chromatography on a FPLC Äkta system. Figure 3 
shows Ubc9 elution in one clean peak monitored by a protein density profile 
measured at 280nm in milli Abosrbance units (mAU). 
In the next step all peak fractions containing high protein amounts and adjacent 
fractions were evaluated by separation on a 12.5% SDS PAGE followed by 
staining of proteins with Coomassie blue. As demonstrated in Figure 4 fractions 
B7 (A280nm measurement: 285.20-289.70ml), B8 (A280nm measurement: 290.05-
294.90ml), B9 (A280nm measurement: 295.25-299.75ml) contained Ubc9 enriched 
to near homogeneity compared to the starting material (ultra SN). In addition 
critical steps of the purification protocols are shown: Ubc9 elution from SP-
sepharose (Ubc9 SP-EL) and the flow through after SP beads incubation (SP 
Figure 4: Steps of Ubc9 
purification. Samples were 
separated by 12.5% SDS-PAGE 
and protein was stained with 
Coommassie brilliant blue. Lane 1 
“ultra SN” shows an aliquote of 
the crude bacterial lysate after 
ultra centrifugation. Subsequent 
Ubc9 was enriched by ion 
exchange chromatography on SP-
beads. “bead FT” or “SP FT” 
indicates the flow through after 
enrichment on the beads whereas 
lane 3 demonstrates an aliquote 
after elution from the beads “Ubc9 
SP-EL”. The eluted protein was 
finally separated by size exclusion 
chromatography and protein 
containing and adjacent fractions 
(FPLC fractions) are shown. 
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Figure 5: Concentration 
determination of purified 
recombinant Ubc9 with the 
reference protein α-
Lactalbumin. A serial dilution of 
Ubc9 was compared to defined 
concentrations of α-Lactalbumin 
as indicated. Samples were 
separated on 12,5% SDS PAGE 
and protein was stained with 
Coomassie blue. Ubc9 
concentration was estimated as 3 
µg/µl. 
FT). Of note, the presence of Ubc9 in the SP-FT sample indicates that the 
binding to SP-sepharose was incomplete. 
1.1.2. Coupling of recombinant Ubc9 to cyanbromide-activated sepharose 
1mg of the recombinant Ubc9 was coupled to cyanbromide-activated sepharose 
which finally served as the matrix for antibody purification. Binding of Ubc9 to the 
beads was verified by investigating aliquots of beads before (“beads before”) and 
after Ubc9 binding (“beads after”) as well as testing the flow through after binding 
(“flow through”). Samples were analyzed by separation on SDS PAGE followed 
by protein staining with Coomassie brilliant blue. As demonstrated in Figure 6, 
recombinant Ubc9 was saturated on beads since the flow through fraction 
contained low Ubc9 levels.  
Figure 6: Coupling of recombinant Ubc9 
to cyanbromide-activated sepharose. 
Ubc9 binding was followed by analysis of 
beads (“beads before”) and after Ubc9 
binding (“beads after”). Ubc9 depletion was 
analysed before (Ubc9 before) and after 
binding (flow through) to the sepharose. 
Samples were separated by 12.5% SDS 
PAGE and protein was stained with 
Coomassie brilliant blue. 
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3.1.2 Affinity purification of anti-Ubc9 specific antibodies 
Affinity purification is performed to obtain antigen specific antibodies with high 
reduction in unspecific background binding. Such antibodies are favored for 
immunoblotting and immunofluorescence analysis. Therefore, the serum from a 
goat immunized with human Ubc9 as antigen, was incubated with the 
recombinant Ubc9 bound to sepharose. 
Elution was done with acidic acid in 1ml fractions, which were immediately 
neutralized and tested for their protein content by spotting small aliquots on a 
nitrocellulose membrane. Protein containing fractions were stained with Ponceau 
S (data not shown), pooled, concentrated to a volume of approximately 500µl and 
buffer exchanged. Aliquotes were stored for further usage at -20°C. 
3.1.3 Specificity and sensitivity of affinity purified anti-Ubc9 antibodies in 
immunoblot analysis  
To determine the specificity and sensitivity of the newly purified antibodies 
different dilutions were tested on crude cell lysates from NIH3T3 mouse 
fibroblasts: 12µg of these protein extracts were separated on a 12.5% SDS 
PAGE and immunoblotted with indicated concentrations of the affinity purified 
anti-Ubc9 antibodies. As shown in Figure 7, antibody dilutions up to 1:4000 
resulted in detection of a single band at approximately 18 kDa, the expected size 
for Ubc9. Also longer exposures exceeding 10 minutes did not indicate any 
significant background staining (data not shown)  
15kDa 
Figure 7: Affinity purified anti-Ubc9 
antibodies in immunoblot analysis: 
12µg crude cell lysates of NIH 3T3 
cells were separated on 12.5% SDS 
PAGE. Ubc9 was detected by 
immunoblotting with indicated antibody 
concentrations. Detection was with 
HRP-labelled secondary antibodies 
followed by chemiluminescence. 
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In summary, the new affinity purified Ubc9 antibodies worked nicely in the 
detection of endogenous Ubc9 in cell extracts. 
3.1.4 Specificity and sensitivity of affinity purified anti-Ubc9 antibodies in 
immunofluorescence analysis  
Since the affinity purified antibodies specifically recognized Ubc9 in immunoblot 
analysis the next question was whether they can also be used for 
immunofluorescence analysis.  
NIH 3T3 fibroblasts were fixed with 2% Formaldehyde in PBS. As for 
immunoblotting also for immunofluorescence different primary antibody dilutions 
were tested in various experiments including 1:100, 1:200, 1:400, 1:500, 1:800, 
Figure 8: Affinity purified anti-Ubc9 antibodies in immunofluorescence analysis. 
NIH 3T3 were fixed with 2% Formaldehyde/PBS and stained with anti-Ubc9 antibodies 
(1:100). Detection was accomplished with an Alexa Fluor®-488-anti-goat secondary 
antibody. DNA was stained with DAPI. Pictures were taken with Zeiss Axiovert 
microscope. Indicated magnification of 40x and 100x. 
Page 15 of 82 
 
1:1000 and 1:1600. As secondary antibody an Alexa Fluor® 488-anti-goat-
fluorophore-coupled donkey-antibody in a 1:1000 dilution was used. Antibody 
dilutions lower than 1:100 showed very weak and diffuse staining without any 
distinct sub-cellular localization. Since this staining was not obtained with the 
secondary antibody alone it is suggested as background staining from the 
primary antibody. Also at the highest antibody concentration (1:100) the staining 
was very weak and nearly at the detection limit for the Zeiss Axiovert camera 
used. 
At the highest magnification of the device (Figure 8 D) Ubc9 showed a faint 
staining in the cytoplasm with a slight enrichment in the nucleus and at the 
nuclear envelope. In earlier studies in HS68 human diploid fibroblasts Ubc9 
levels were much more pronounced in the nucleus compared to the cytoplasm75. 
This suggests that either Ubc9 expression differs between mice and human 
fibroblasts or that Ubc9 is expressed at levels below the detection limit for the 
newly purified antibody. To distinguish between these scenarios a HA (human 
influenza hemiglutinin) tagged version of Ubc9 was transiently expressed and 
immunofluorescent staining was performed with a monoclonal anti-HA antibody 
recognizing the tag. Whereas this antibody showed a distinct staining as 
Figure 9: Transient transfection of Hela cells with pCruz HA-Ubc9. Hela were fixed 
with 2% Formaldehyde/PBS and stained with anti HA monoclonal antibody (1:1000) 36h 
after transfection. Detection accomplished with an Alexa Fluor®-488-anti-mouse 
secondary antibody. DNA was stained with DAPI. Pictures were taken with Zeiss Axiovert 
microscope. Indicated magnifications 63x (A merge: anti-HA+DAPI) and 40x (B:anti-HA)  
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Figure 10: Tet-on 3G Gene Induction: The transactivator protein (blue) undergoes a 
conformational change in the presence of Doxycycline which causes its binding to the Tet 
responsive element (black; TRE) consisting out of multiple copies of the signal sequence 
for the Tet protein. This in turn induces the transcription of Ubc9 downstream of a minimal 
Cytomegalovirus promoter (white). 
presented in Figure 9, the staining with the purified anti-Ubc9 antibodies again 
was too weak for taking comparative pictures. This initial immunofluorescence 
analysis of the affinity purified anti-Ubc9 antibodies did not lead to conclusive 
results and more conditions (fixing, higher antibody concentrations) will need to 
be tested.  
3.2 Ubc9 overexpression in NIH 3T3 mouse fibroblasts 
The generation of an inducible stable Ubc9 overexpression cell line was the 
central part of this research project. Creating such a system aimed to establish a 
model for high Ubc9 expression, as it was often found in cancer tissues of 
various origins. Concomitant with elevated Ubc9 expression, tumor cells acquired 
crucial properties for tumor survival, as for instance increased metastasis and 
evading chemotherapy. Thereby, the inducible Ubc9 overexpression aimed to 
study whether the elevated Ubc9 level is a driver for tumor formation or rather a 
secondary hit in progressed cancer stages. To answer that question, the Tet-On® 
3G expression system was used. That system was reported to have a sensitive 
responsiveness to the expression-activating tetracycline-derivate Doxycycline 
(Dox) with only low baseline expression levels. At that time it was the newest 
version of Tet systems which is also applicable for related mice studies planned 
in the future. There the addition of Dox to the drinking water would induce 
transgene expression.  
Page 17 of 82 
 
In the Tet-On® 3G system a stable cell line needed to be generated, which 
constitutively expressed a transactivator protein (TetA). In a second transfection 
the expression plasmid was introduced containing Ubc9 downstream of the TetA-
responsive promoter. In the presence of Dox, TetA underwent a conformational 
change and could only then bind to repetitive sequences (TRE) upstream of the 
responsive promoter. By that, the minimal CMV promoter was activated and 
transcription of Ubc9 was induced (Figure 12). 
3.2.1 Generation of stable inducible cell lines using the Tet transactivator 
system  
3.2.1.1 Tet Transactivator expression analysis by immunoblotting 
The prerequisite for inducible Ubc9 overexpression was the generation of a cell 
line expressing TetA. After transfection of the pCMV-TetA plasmid cells were 
selected for resistance to G418. That was due to the co-expression of the 
antibiotic resistance marker neor on the transfected plasmid. G418 is also named 
Geneticin® and inhibits the 80S ribosomal subunit essential for the protein 
translation of eukaryotic cells. Expression of the neor gene protects the cells from 
the antibiotic action of G418. 76 That neor gene is placed downstream of an SV40 
early promoter on the pCMV-Tet3G plasmid (Clontech). Seven clones were 
isolated and tested for TetA protein expression after induction with 1µg/ml Dox for 
48h and immunoblotting of 20µg total cell lysates. 
Wild type NIH 3T3 cells were included to monitor any physiological deviation 
caused by the applied concentration of Dox in the growth medium and as 
negative control for TetA expression. To test the impact of Dox on TetA 
expression lysates from induced as well as un-induced TetA cells were 
compared. Cells denoted clone 7 was the only clone out of the seven resistant 
clones that produced a high level of the transactivator protein (Figure 11).  
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3.2.1.2 Functional dual luciferase reporter gene assay 
A dual reporter gene assay was used to assess the capability of the isolated TetA 
clones to induce gene expression measured with the Firefly Luciferase reporter 
gene. The screening of a reporter gene like Luciferase was easier to measure 
than the TetA expression and much more sensitive than immunoblotting. 
Moreover, it allowed the more accurate quantification of target gene induction 
than determining the ability to express Ubc9. The chemical Luciferase reaction 
produces light in a linear intensity over a wide range77. Due to its absence in the 
mouse genome, Luciferase does not produce any background noise from 
endogenous expression. Additionally, the co-transfection of a constitutive 
expression plasmid containing the Renilla Luciferase gene normalized the 
experiment in terms of varying transfection efficiency, protein concentration and 
any pipetting errors. That was because chemical structures of firefly (Photinus 
pyralis) and Renilla Luciferase (Renilla reniformis) molecules are different which 
results in different substrate requirements. So, it was possible to measure them 
sequentially. 
The readout of the Luciferase activity confirmed the initial screen of the clones by 
the immunoblot giving the by far highest Luciferase expression for the new TetA 
clone 7 cells (Figure 12, red bar). A previously established Tet-on cell line was 
included in that experiment, because they failed to produce detectable protein 
amounts when used as positive control in the immunoblot before. Its potential to 
induce Luciferase expression after multiple cell passages (green bar) was also 
Figure 11: Dox-inducible 
expression of the transactivator 
protein. NIH 3T3 cells transfected 
for TetA protein expression after 
selection by G418. 20µg of total cell 
lysate were separated on 12.5% 
SDS PAGE. Ubc9 was detected by 
immunoblotting with 1:500 
commercial monoclonal mouse 
TetR antibody Detection was with 
HRP-labelled secondary antibodies 
followed by chemiluminescence. 
Cells were incubated with or without 
1µg/ml Doxycycline (Dox) for 48h. 
Beta-Tubulin as loading control 
confirms similar protein amounts.  
55kDa
35kDa
40kDa
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Figure 12: Induction of the Luciferase 
reporter gene. Seven NIH 3T3 clones 
 stably transfected with pCMV-TetA for 
the constitutive transactivator expression 
were transiently transfected with a 
pTre3G-Luciferase plasmid and assayed 
for induction of Luciferase. The cells were 
induced with 3µg/ml Doxycycline (Dox) for 
24h and then analysed for Luciferase 
activity which is proportional to induced 
gene expression. Clone 7 performed best 
compared to all other clones. Former 
established NIH 3T3 Tet-on cells were 
used as positive control. 
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lower than for the early passage of the actual TetA cells. Their Luciferase gene 
expression represents less than 10% of the new clone 7 (87.6 versus 931.5 fold 
induction). Besides that, only clone 2 showed some rather low induced 
expression of Luciferase (70.6 fold induction) whereas all other clones did not 
exceed a 10-fold induction relative to the negative control.  
Moreover, concentrations above 1µg/ml Doxycycline did not elevate the induced 
expression level of Luciferase. Higher Dox concentrations thereby rather 
decreased than increase the fold induction of Luciferase (not shown). 
The evaluation of TetA protein expression by immunoblotting and the level of 
Luciferase reporter gene induction qualified clone 7 for the generation of a stable 
Ubc9 inducible cell line. 
3.2.1.3 Transient Ubc9 overexpression 
To test the potential to induce Ubc9 cloned into the pTre3G-Ubc9 expression 
plasmid it was transiently expressed in the established stabe TetA expressing cell 
line. Cells were transfected with pTre3G-Ubc9 in medium containing or not 
containing Dox which was added together with the Fugene transfection reagent 
for 48h hours. Cells were lysed in SDS buffer and 10µg of total cell lysates from 
Dox-induced and non-induced cells were compared by immunoblotting after 
separation on SDS-PAGE. As shown in Figure 13, in the presence of 1µg/ml Dox 
for 48h Ubc9 expression was nicely induced compared to the non-induced 
endogenous Ubc9 levels (Figure 13). Of note, the Dox dependent induction of 
Page 20 of 82 
 
Ubc9 is even higher since only approximately half of the cells were transfected as 
monitored by eGFP expression (not shown). That implies that the Ubc9 levels per 
cell are even higher as it appears in immunoblotting. In summary this results 
clearly show that Ubc9 expression can be nicely induced upon Dox induction in 
the stable TetA expressing cells. 
3.2.2 Establishing a stable Ubc9 inducible cell line 
Since transient expression only targets approximately 50% of the cells and the 
levels of expression differ from cell to cell, the establishment of a homogeneous 
stable Ubc9 inducible cell line was conceived. Therefore, NIH 3T3 TetA cells 
were co-transfected with the pTre3G-Ubc9 and a linear Hygromycin restance 
marker required for selection of transfected cells. Hygromycin B is an 
aminocyclitol antibiotic inhibiting 70S and 80S large ribosomal subunits and is 
produced by the gram positive bacterium Streptomyces hygroscopicus. 78 The 
Hygromycin B phosphotransferase found in the same organism confers 
resistance to that antibiotic79. 30 hours after transfection, the cells were 
challenged with 150µg/ml Hygromycin B in the growth medium for approximately 
two weeks. While the untransfected cells are supposed to die during that time, 
cells which express both transfected plasmids are expected to form large 
resistant colonies. These colonies were individually isolated and separated in 24 
well plates were they grew to at least 60% confluence. 20 clones were obtained 
after this procedure and subsequently analyzed by a genotyping PCR. 
The PCR was designed to evaluate each clone for the integration of the pTre3G-
sUbc9 expression plasmid into its genome. This step was necessary to exclude 
Figure 13: Transient transfection of NIH 
3T3 TetA cells with pTre3G-Ubc9. NIH 3T3 
TetA cells were transiently transfected with the 
pTre3G-Ubc9 plasmid and expression was 
induced with 1µg/ml Doxycyline for 48h. 10µg 
crude SDS-cell lysates were separated on 
12.5% SDS PAGE. Ubc9 was detected by 
immunoblotting with Ubc9 antibodies (1:1000). 
Detection was with HRP-labelled secondary 
antibodies followed by chemiluminescence. 
Beta-Tubulin confirms that similar protein 
amounts were loaded.
55kDa
15kDa
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Figure 14: Genotyping PCR of stable NIH 3T3 TetA-pTre3G-Ubc9 clones. The 
genomic DNA of NIH 3T3 TetA cells transfected with pTre3G-Ubc9 plasmid and resistant 
to Hygromycin B was genotyped. Thereby, the primers enclosed the pTre3G promoter 
sequence at the 5’-end and the Ubc9 3’ end. 10µl of the PCR reaction were separated on 
2% agarose gels and detection with UV-light and gel red. Negative clones were excluded 
from further analysis. The negative controls were TetA cells which were not transfected, 
the H2O control contained water instead of DNA. pTre3G was the positive control which 
contained 10ng of pTre3G-Ubc9 expression plasmid.
false positive clones which integrated only the linear Hygromycin resistance 
gene, but not the circular plasmid for conditional Ubc9 expression. For PCR 
analysis the genomic DNA of each cell line was extracted and 500ng/µl or less 
was amplified with primers enclosing the 5’ promoter sequence of the pTre3G 
plasmid and the Ubc9 3’ end to distinguish the endogenous from the exogenous 
Ubc9.  
As shown in Figure 14 indeed 16 out of 20 clones integrated the pTre3G-Ubc9 as 
detected by PCR amplification and subsequent agarose gel electrophoresis 
(Figure 14). In the next step all positive pTre3G-Ubc9 positive clones were further 
tested for their ability to inducibly express Ubc9 after induction with Dox. The cell 
lines with the strongest signals in the PCR reaction were the most promising 
candidates for inducible Ubc9 expression. 
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3.2.3 Inducible Ubc9 expression in stable NIH 3T3 TetA-pTre3G-Ubc9 cell 
lines 
After genotyping, only clones which had integrated the Ubc9 expression plasmid 
into their genome were tested for inducible Ubc9 overexpression. The biological 
function of Ubc9 was expected to be completely retained since an untagged 
human Ubc9 sequence was cloned into the pTre3G plasmid. The human and the 
murine Ubc9 genes share 93% sequence homology when aligned in a BLAST, 
whereas the amino acid sequences are 100% identical. In order to evaluate the 
cell lines for their Ubc9 protein expression levels, all NIH 3T3 pTre3G clones 
were induced with 1 to 3µg/ml Dox for 24 to 96 hours. After that treatment cells 
were lysed in SDS buffer and separated on SDS PAGE. Analysis was by 
immunoblotting with anti-Ubc9 anitbodies. Figure 15 is representative for all 
clones which had been positive for the pTre3G-Ubc9 in PCR genotyping. In the 
example presented, clone 4, clone 6, clone 9 and clone 11 were evaluated for 
their Ubc9 overexpression after induction with 1µg/ml Dox for 48h. The cell 
lysates were compared to an equally induced stable empty vector control clone 
(V) which was transfected with the pTre3G backbone. 
Disappointingly, not a single of the pTre3G–Ubc9 positive clones showed 
increased Ubc9 levels after Dox induction at any tested condition. In summary, 
although being resistant to Hygromycin as well as having the Ubc9 expression 
plasmid integrated into the genome, none of the clones was inducible for Ubc9 
overexpression. This data clearly indicate that the tet- inducible system is not 
15kDa 
Figure 15: Inducible Ubc9 expression in NIH 3T3 TetA clones. Stable clones #4, 6, 9 and 11, 
positive for pTre3G-Ubc9 in geneotyping were treated as indicated with 1µg/ml Doxycycline 
(Dox) for 48 hours. were tested for induced Ubc9 expression. 10µg crude SDS. cell lysates were 
separated on 12.5% SDS PAGE. Ubc9 was detected by immunoblotting with Ubc9 antibodies 
(1:1000). Detection was with HRP-labelled secondary antibodies followed by 
chemiluminescence. V: cells stably transfected with the pTre3G backbone was used as negative 
control 
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suitable to obtain inducible Ubc9-overexpressing cells and other strategies have 
to be established. 
3.3 Ubc9 Knock Down 
The approach to transiently knock down Ubc9 was an alternative attempt to 
deregulate Ubc9 and to investigate changes in heterochromatin. Due to the fact 
that SUMOylation was found to be a modification of enzymes responsible for 
repressive chromatin modifications the knock down of Ubc9 was hypothesized to 
result in changes of heterochromatin57, 66, 105.  
3.3.1 Individual siRNA sequences differentially reduce Ubc9 
In that experiment, the fundamental set up for the Ubc9 knock down was 
evaluated by immunoblotting (Figure 16). NIH 3T3 cells were separately 
transfected with three different siRNAs targeting different exons and a control 
pool of non targeting RNAs (scrambled control, Sc). All three individual siRNAs 
reduced endogenous Ubc9 levels, although at different levels. The best result 
was obtained with siRNA1. However, the pool of all three specific Ubc9 siRNAs 
was even a bit more efficient. Ubc9 reduction was already observed after 24h 
(not shown) but the best reduction was obtained after 48h. 
In summary, treatment of a pool of Ubc9 targeting siRNAs for 48 hours was 
established as standard method for all further knock down experiments. 
Figure 16: Ubc9 knock down in 
NIH 3T3 cells with 3 siRNAs. Cells 
were transfected with three individual 
Ubc9 targeting siRNA sequences for 
48h. Each sequence was compared 
to the pool consisting of all three 
siRNAs of equal concentration. 
Immunoblotting of 10µg crude cell 
lysates of NIH 3T3 cells were 
separated on 12.5% SDS PAGE. 
Ubc9 was detected by 
immunoblotting with Ubc9 antibodies 
(1:1000). Detection was with HRP-
labelled secondary antibodies 
followed by chemiluminescence. 
siRNA: small interfering RNA, Sc: 
Scrambled control, pool of non-
targeting siRNAs 
55kDa
15kDa
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3.3.2 Ubc9 is knocked down for 72h 
The next question asked was when Ubc9 will reappear after the RNAi knock 
down. Determination of the time frame of Ubc9 depletion was crucial for further 
analysis to investigate changes in the Histone methylation. Thus, the Ubc9 knock 
down was investigated in a time course for five days.10µg protein samples of 
total cell lysates were generated after 24h, 48h, 72h, 96h and 120h. In parallel, 
the cells were monitored in the light microscope for any differences in 
morphology and growth. 
Immunoblotting analysis indicated that up to 72 hours, Ubc9 was not detectable 
and slowly appeared after 96 hours (Figure 17). Analysis in light microscopy 
indicated that cells treated with Ubc9 siRNAs showed an increase in rounded and 
dead cells starting from day two onwards compared to the normal growing cells 
treated with scrambled siRNAs. This finding is in line with earlier studies reporting 
that Ubc9 is essential for mammalian cell growth37.  
In summary, a siRNA mediated Ubc9 knock down was successfully established 
was with a pool of three siRNAs in NIH3T3 cells. So, this method was then 
further used to study the consequences of Ubc9 deregulation on heterochromatin 
formation.  
3.3.3 Histone Methylation changes in Ubc9 Knock down cells 
Different studies indicated that the sumoylation machinery is implicated in the 
formation of heterochromatin-like structures in euchromatic loci64, 66. The feature 
of such facultative heterochromatin is characterized by low levels of activating 
histone marks like histone acetylation and histone H3K4 methylation but high 
Figure 17: Time course of 
Ubc9 knock down. 10µg. 
crude cell lysates of NIH 3T3 
cells were separated on 12.5% 
SDS PAGE. Ubc9 was detected 
by immunoblotting with Ubc9 
antibodies (1:1000). Detection 
was with HRP-labelled 
secondary antibodies followed 
by chemiluminescence. siRNA: 
small interfering RNA, Sc: 
Scrambled control 
15kDa
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Figure 18: Concentration 
determination and purity test 
of Histone acid extracts. 
Histones were purified from 
NIH 3T3 cells treated with 
Ubc9 siRNAs for 48h Ubc9 
siRNA knock down cells by 
extraction with hydrochloric 
acid and compared to a 
defined concentration of α-
lacalbumin standards by SDS 
PAGE. Detection was by 
staining with Coomassie 
brilliant blue. H: histone 
levels of repressing marks including DNA methylation and H3K27 methylation, 
H3K9 di-and trimethylation and H3K20 mono-, di- and trimethylation113. The aim 
of this work was to analyse if changes in heterochromatin specific histone marks 
can be detected after Ubc9 knock down. 
3.3.3.1  Preparative histone acid extraction 
To test whether histone methylation is affected in Ubc9 knock down cells, first 
global changes of various histone methylations by immunoblotting of purified 
histones were investigated. Because of their net positive charge histones can be 
purified by acid extraction of cell nuclei. Determination of the histone 
concentration was done by visual comparison of different dilutions of purified 
histone extracts to defined concentrations of alpha-lactalbumin separated on 
SDS PAGE and stained with coomassie brilliant blue (Figure 18). That assay 
allowed not only the quantification of the individual histone concentrations, but 
also provided information of the quality of the histone preparation. 
After establishing that preparative method global changes of the histone 
methylation in Ubc9 knock down cells could be subsequently studied by 
immunoblotting. 
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Figure 19: Immunoblot analysis of 
histone lysine methylation: Equal 
concentrations of histone acid extracts 
from NIH 3T3 cells transfected with Ubc9 
or scrambled (Sc) siRNAs were separated 
on SDS PAGE. Immunoblotting was with 
indicated antibody (1:1000). Detection was 
with HRP-labelled secondary antibodies 
followed by chemiluminescence. Knock 
down was controlled by immunoblotting 
with anti-Ubc9 antibodies. 
3.3.3.2  Analysis of histone methylation of NIH 3T3 cells upon Ubc9 knock down  
To gain insights into the consequences of Ubc9 down regulation on 
heterochromatin formation, NIH 3T3 cells were transfected with either Ubc9 
targeting or scrambled siRNAs for 48 hours. Analysis was done with a variety of 
antibodies detecting specific repressive histone methylation marks80, 81, 82, 83, 84, 85, 
86, 87, 88, 89, 90, as shown in Figure 19. To confirm that equal concentrations of 
histones were loaded to the gel lanes, an antibody recognizing the histone H3 
core was used. Under conditions where Ubc9 was significantly reduced no 
difference could be detected for mono-, di- and trimethylation of the histone H3 at 
lysine 9 and lysine 27 (H3K9, H3K27). Monomethylation of histone H4 at lysine 
20 seemed slightly enhanced in Ubc9 knock down. In contrast, the enhancement 
of histone H4 di- and tri-methylation at lysine 20 (H4K20me2, H4K20me3) in 
histones extracted from Ubc9 knock down cells was much more pronounced. 
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Together studying different repressive heterochromatin marks after Ubc9 knock 
down indicated increased levels of H4K20 mono-, di- and trimethylation whereas 
all different stages of H3K9 and H3K27 methylation did not change. 
3.3.3.3 Analysis of pericentric heterochromatin changes upon Ubc9 knock down 
in NIH 3T3 cells 
Another method to study general changes in heterochromatin is by 
immunofluorescence analysis. Pericentric heterochromatin, a major repressive 
chromatin mark can be visualized as DAPI-dense foci in interphase nuclei of 
NIH3T3 cells. Different repressive chromatin marks are enriched at pericentric 
heterochromatin including DNA methylation, H3K9m3 and H4K20m3.  
Since downregulation of Ubc9 indicated unchanged H3K9m3 levels but increased 
H4K20m3 levels in immunoblot analysis these studies were continued with the 
analysis of pericentric heterochromatin in immunofluorescence stainings. 
Therefore, NIH 3T3 cells were transfected for 48 hours in microscopy chamber 
slides with either the pool of siRNAs specific for the Ubc9 knock down or with 
scrambled siRNAs, as control. The transfections were performed in quartets to 
confirm on one hand the efficiency of the knock down and on the other hand to 
analyze the cells for the two prominent pericentric heterochromatin marks 
H3K9m3 and H4K20m3 in immunofluorescence stainings. The knock down of 
Ubc9 in the microscopy chambers was verified by separating whole protein from 
curde cell lysates on a 12.5% SDS PAGE gel and immunoblotting was with Ubc9 
antibodies (Figure 20). For immunofluorescence analysis cells were fixed with 2% 
Formaldehyde and stained with antibodies raised in rabbits specific for the 
H3K9me3- or the H4K20me3-antigens. Detection was done with a fluorescent 
labelled Alexa Fluor®-488-anti-rabbit antibody. In the first wash after the 
Figure 20: Ubc9 knock down in microscopy chamber 
wells. Cells were transfected with Ubc9 or scrambled (Sc) 
siRNA pool for 48h. Each Immunoblotting of 10µg crude cell 
lysates of NIH 3T3 cells were separated on SDS PAGE. Ubc9 
was detected by immunoblotting Ubc9 antibodies (1:1000). 
Detection was with HRP-labelled secondary antibodies 
followed by chemiluminescence. siRNA: small interfering RNA 
15kDa 
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secondary antibody DAPI was added to the washing buffer to stain the DNA. This 
allowed the detection of highly condensed DNA enriched in foci which indicate 
pericentric heterochromatin. Slides were finally mounted with DAKO mounting 
medium. 
 
Figure 21: Immunofluorescence staining of H3K9me3 in 48h NIH 3T3 cells upon Ubc9 
knock down: Cells were fixed with 2% Formaldehyde/PBS and stained with anti H3K9me3 
antibodies (1:1000). Detection was accomplished with an Alexa Fluor®-488-anti-rabbit 
secondary antibody. DNA was stained with DAPI. Pictures were taken with Zeiss Axiovert 
Apotome microscope at magnification of 40x and 100x, as indicated.A: DAPI of scrambled 
control (Sc), B,C: H3K9me3 staining of scrambled control in 40x (B) and 100x magnifications 
(C), D: DAPI of Ubc9 knock down, E,F: H3K9me3 Ubc9 knock down in 40x (E) and 100x (F) 
magnifications.  
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Images were taken in 40-times and 100-times magnifications with the Zeiss 
Axiovert Apotome Imagining microscope. Equal exposure times were applied to 
normalize for the intensity of the stainings. The Apotome device mimicked a 
Figure 22: Immunofluorescence staining of H4K20me3 in 48h NIH 3T3 cells upon 
Ubc9 knock down cells: Cells were fixed with 2% Formaldehyde/PBS and stained with 
anti H4K20me3 antibodies (1:1000). Detection was accomplished with an Alexa Fluor®-
488-anti-rabbit secondary antibody. DNA was stained with DAPI. Pictures were taken with 
Zeiss Axiovert Apotome microscope at magnification of 40x and 100x, as indicated.A: 
DAPI of scrambled control (Sc), B,C: H4K20me3 staining of scrambled control in 40x (B) 
and 100x magnifications (C), D: DAPI of Ubc9 knock down, E,F: H4K20me3 Ubc9 knock 
down in 40x (E) and 100x (F) magnifications.
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confocal scanning of the sample by applying a static as well as a moving optical 
grid. Thus, the software eliminated the scattered light which was not in the focal 
plane. 
In agreement with the immunoblot analysis also the immunofluorescence staining 
of H3K9me3 did not reveal any significant difference in heterochromatin 
formation in cells upon Ubc9 knock down compared to the control cells (Figure 
21). The foci that are indicative for densely packed heterochromatin remained 
unaltered in their number and intensity when Ubc9 was knocked down. 
Histone H4K20me3 was significantly increased upon Ubc9 knock down in 
immunoblot analysis which may result in changes in pericentric heterochromatin. 
Figure 23: Immunofluorescence staining of H4K20me1 in 48h NIH 3T3 cells upon 
Ubc9 knock down: Cells were fixed with 2% Formaldehyde/PBS and stained with anti 
H4K20me1 antibodies (1:1000). Detection was accomplished with an Alexa Fluor®-488-
anti-rabbit secondary antibody. DNA was stained with DAPI. Pictures were taken with 
Zeiss Axiovert Apotome microscope at magnification of 40x. A: DAPI of scrambled control 
(Sc), B: H4K20me1 staining of scrambled control, C: DAPI of Ubc9 knock down, D: 
H4K20me1 Ubc9 knock down in 40x 
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Therefore also H4K20me3 staining was performed as described above for 
H3K9me3. As shown in Figure 22, although the number and shape of 
heterochromatic foci did not change significantly in the cells upon Ubc9 knock 
down. It appears that more cells are showing higher intensity in H4K20me3 
staining in the cells upon Ubc9 knock down compared to the control cells. 
Ubc9 depletion results in a G2/M arrest of the cell cycle109. H4K20me1 is a highly 
dynamic chromatin mark which significantly changes during the different cell 
cycle phases. It appears in S-phase and is highly enrichment in G2/M and at 
meiotic chromosomes 91, 92. Therefore, I also investigated H4K20me1 in NIH3T3 
cells upon Ubc9 knock down. As it is demonstrated in Figure 21 the control cells 
show a very heterogeneous population of H4K20me1 positive cells whereas in 
the Ubc9 knock down all cells showed a strong enrichment in H4K20me1 staining 
confirming a Ubc9 depletion induced G/2M arrest. 
In conclusion, immunofluorescence analysis of Ubc9 depleted cells confirmed a 
significant enrichment in H3K9me3 modification but did not indicate a difference 
in DAPI dense foci number or foci shape. Also the cell cycle regulated 
modification, H4K20me1 was highly enriched, that Ubc9 depletion induced a cell 
cycle arrest at G2/M (Figure 22, Figure 23). 
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4 Discussion 
Sumoylation is an essential posttranslational modification involved in most 
cellular pathways. SUMO is covalently linked to its substrates via a hierarchical 
enzymatic cascade involving one E1 activating, one E2 conjugating and several 
substrate specific E3 ligating enzymes. Although regulation is mainly performed 
by E3 ligases different studies point to an important role for the sole SUMO E2 
enzyme Ubc993, 94. Its upregulation promotes cell invasion and metastasis and is 
found in different types of cancers whereas its depletion is lethal in mice and 
results in severe chromosomal defects and major changes in the nuclear 
architecture95, 96, 97, 98, 99, 100, 101, 102, 103. 
In line, sumoylation was demonstrated to be implicated in the formation of 
heterochromatin, highly condensed chromosomal regions characterized by low 
levels of transcriptional activating histone marks (e.g. acetylation and histone 
H3K4 methylation) but high levels of repressing marks (e.g. DNA methylation and 
H3K27 methylation, H3K9 di-and trimethylation and H4K20 mono-, di- and 
trimethylation)104, 105, 106, 107. The aim of this work was to analyze if deregulation of 
Ubc9, either by overexpression or by down regulation, results in overall changes 
of such heterochromatin specific histone marks.  
To study Ubc9 overexpression a Dox inducible system in NIH3T3 cells was 
established. Although several clones with the inserted plasmid were obtained, 
none of them showed inducible Ubc9 expression.  
Analysis of Ubc9 down regulation mediated by a pool of three siRNAs resulted in 
significantly reduced Ubc9 levels in NIH3T3 cells. This system then allowed the 
analysis of diverse repressive heterochromatin marks by immunoblot and 
immunofluorescence studies. Initial immunoblot analysis did not indicate severe 
changes in mono-, di- and trimethylation of H3K9 and H3K27. Interestingly, an 
increase in all stages (mono-, di- and tri) of H4K20 methylation was obtained. 
The most severe difference was observed with H4K20me3 which was further 
investigated in immunofluorescence staining. Also with this approach, the 
increase in H4K20me3 was detected upon Ubc9 knock down but only the 
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intensity of foci representative for heterochromatin was enhanced rather than a 
change in shape or number. 
Ubc9 knock down results in a G2/M cell cycle arrest and H4K20me1 fluctuates 
during the cell cycle with high enrichment in G2/M and at mitotic 
chromosomes108. Therefore, also this particular histone mark in 
immunoflourescence staining was investigated. Indeed, H4K20me1 is enriched in 
all cells upon Ubc9 knock down confirming a G2/M arrest. This finding raises the 
question whether Ubc9 down regulation is directly involved in H4K20me1 
enrichment or whether it is just the consequence of the induced cell cycle arrest. 
Support for a direct role for Ubc9 in regulating H4K20me1 comes from a recent 
study demonstrating PR-Set7, the key enzyme for setting H4K20me1, as SUMO 
substrate109. 
The identification of increased H4K20 methylation upon Ubc9 down regulation 
strengthens the crosstalk between sumoylation and chromatin. The different 
stages of H4K20 methylation are involved in several biological pathways 
including transcription, DNA repair and heterochromatin formation110. These are 
all pathways in which sumoylation is also known to play a major regulatory 
function111, 112, 113. Therefore, it will be of key importance to further dissect the link 
between the regulation of the SUMO system and their consequences on 
chromatin. 
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6 Materials and Methods 
6.1 Amplification of plasmid DNA 
All the plasmids used in this study had been already cloned and were taken from 
frozen stocks. These plasmids had been sequenced and used before by other 
scientists. Thus, in an initial working step personal plasmid stocks were 
produced. That was done by transformation of bacteria followed by purification of 
the plasmid DNA with a kit. 
6.1.1 Heat shock transformation 
For all Midipreps, competent (processed by the technical assistant, S Koidl) 
E.Coli DH5α cells were used. Therefore, 100µl of bacteria were thawed on ice, 
~1.5µg of the respective plasmid was added, mixed by pipetting and incubated 
on ice for 30 min. After a heat shock at 42°C (Eppendorf Thermomixer Comfort) 
for 45s, bacteria were incubated on ice for 3 min. Next, 900µl of LB-medium (5g/l 
yeast extract, 5g/l NaCl, 10g/l bacto-tryptone, pH7, room temperature) were 
added, and the mix was transferred to 14ml bacterial growth tubes (Falcon) and 
incubated at 37°C with 170-200rpm shaking (New Brunswick Scientific Innova® 
44) for 1h. 
In the meantime, a petri dish with agar containing the appropriate antibiotic 
(Ampicillin: 100µg/ml, or Kanamycin: 50µg/ml) (for the corresponding resistance 
gene) on the plasmid were prewarmed at 37°C. Finally, bacteria were spun down 
at 4000rpm (~1500rcf) for 5 min and the supernatant was discarded. The pellet 
was resuspended in the remaining volumeand plated on the agar plate, 
distributed using a glass spreader and then incubated at 37°C over night. 
The next day, a single colony was picked using an inoculation needle or a sterile 
pipette tip and transferred to a bacterial growth tube containing 5ml LB containing 
the same type and concentration of antibiotic. That starter culture was incubated 
at 37°C with shaking for 4 to 8h. After that, depending on the OD600 density of 
the culture, an aliquot or the whole starter culture was scaled up in 100ml of the 
same selective medium in a 300ml or larger Erlenmeyer flask. 
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For the pCruz plasmids, usually giving low yields, Chloramphenicol was added to 
the culture the next day for approximately 4h to block translation and thus to 
enhance plasmid synthesis.  
6.1.2 Plasmid purification 
For the large scale purification of plasmid-DNA, the PureLink™ Hipure Plasmid 
Filter Midiprep kit (Invitrogen) was used. The procedure was done according to 
the manufacturers’ instructions with the following amendments: The cells were 
harvested for 15min by centrifugation (Eppendorf Centrifuge 5810R, rotor: A-4-
81) instead of 10min, the optional washing step of the column filter cartridge was 
performed to increase the yield, the plasmid-DNA was precipitated using a 50ml 
instead of a 15ml Falcon tube, and centrifugation after isopropanol precipitation 
as well as after ethanol washing was done at 4000rpm (3113rcf - maximum 
speed) for 45-60min and 15min instead of 15x103g for 30min or 10min, 
respectively. 
The pellet was resuspended in 50-100µl TE-buffer provided in the kit and 
concentration was determined using the Nanodrop 1000 (Thermo Scientific). 
Subsequently, plasmids were stored at -20°C and always thawed and kept on ice 
prior to use. 
6.2 Cell culture of NIH 3T3, NIH 3T3 Tet-On and NIH 3T3 Tet-off 
6.2.1 Maintenance  
The NIH 3T3 cell line (a generous gift from Thomas Jenuwein) was routinely 
maintained in 10 centimetre dishes (BD Falcon) at 37°C/5% CO2 (Heracell 240i, 
Thermo Scientific) in complete medium: Dulbecco’s Modified Eagles Medium 
(DMEM; Sigma Aldrich) supplemented with 10% FBS (Fetal bovine Serum) gold 
(PAA), 1x Glutamax (Gibco, 100x stock), 1xPenecillin/Streptomycin (Sigma 
Aldrich, 100x stock) and 1x Non-essential Amino acids (Sigma Aldrich, 100x 
stock). Microscopic evaluation of cells was done on a regular basis in 5x and/or 
10x magnification (Zeiss, Axiovert 40 CFL) and cells were split in a ratio of 
maximum 1:8 every two to four days. Thereby they were exclusively handled in 
the laminar flow hood (Heraeus Herasafe K12, Thermo Scientific), where the 
medium was aspirated (Vacuu Hand Control, vacuubrand; house aeration), 
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cultures gently washed once with sterile prewarmed 1xPBS (PAA), chemically 
detached with 1ml of pre-warmed (Memmert UNB 400 heating cabinet) 1x 
Trypsin-EDTA (Sigma Aldrich, stock 10x) in 1xPBS for three to five minutes at 
37°C/5% CO2, which was then inactivated with 2ml of complete medium. After re-
suspension of cells with the 1ml Pipette (Gilson, filter tips: greiner bio one), they 
were transferred to a 15ml Falcon tube and spun down at 300g (Heraeus 
Megafuge 16, Thermo Scientific, rotor: Thermo Scientific 75003629) for 5min. 
The pellet was resuspended in complete medium and the sufficient volume was 
added to a new 10cm dish containing five to eight millilitres (ml) of fresh, pre-
warmed, complete medium. 
The same procedure was applied to the NIH 3T3 Tet-On and the NIH 3T3 Tet-off 
cell lines except for the fact that the medium additionally contained 100µg/ml 
G418 (G418 disulfate biochemica, AppliChem, stock 1g lyophilized, diluted to 
working concentration of 10mg/ml in DMEM). 
For freezing of cells, trypsinized cells were spun down again after passaging as 
described, to be then re-suspended in FBS containing 10% DMSO (Sigma). 
Thereof, 1ml aliquots were put into cryovials (Greiner-bio one) which were 
transferred to freezing containers (Nalgene) containing Isopropanol (Sigma 
Aldrich) and stored at -80°C (Sanyo MDF-U73V) for at least 24h. After that, they 
were shifted to -150°C (Sanyo MDF-1155) for long term storage. Cells were 
thawed rapidly in the 37°C waterbath (Stuart SBS40 or GFL 1008) and then 
immediately pelleted as mentioned above and re-suspended in complete 
medium. After plating them, the cells were given time to recover for at least two 
days. 
6.2.2 Generation of stable cell lines 
The Tet-on3G system for the inducible Ubc9 expression demanded a double-
stable cell line. In a first transfection and selection a cell line was generated that 
stably expressed the transactivator protein as confirmed by immunoblot. The 
evaluation whether the expressed TetA level can induce a target gene, a 
Luciferase expressing plasmid was transiently transfected and expression was 
induced. The luminescent readout was directly proportional to gene induction. In 
a second step the best TetA cell line was used for the transfection with the 
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expression plasmid containing the TetA responsive promoter upstream of the 
gene of interest. After the selection, the resistant clones were screened by 
genotyping PCR and by immunoblotting of induced versus non-induced cell 
lysates. 
6.2.2.1 Stable cell lines for Tet-On 3G transactivator protein expression 
For the generation of stable cell lines expressing the transactivator (TetA), 1x105 
NIH 3T3 cells were seeded per well of a 6-well-plate (Corning Incorporation 
Costar) one day prior to transfection to yield a culture of approximately 60% 
confluency. The transfection was performed using the Polyfect reagent (Qiagen). 
The plasmid containing the gene for the TetA was the commercial pCMV-Tet3G 
plasmid from the Tet-On 3G inducible expression system (Clontech). For the 
transfection, the suggested optimized protocol of Polyfect was followed in terms 
of reagent to DNA ratio. So, for one well of a 6-well-plate, 1.5µg of plasmid well 
mixed by vortexing with 100µl of DMEM, followed by addition of 10µl of Polyfect 
were added. Again, the tube was mixed well by vortexing, spun down for 3s to 
avoid any drops at the sides or on the lid and then incubated for 30min at room 
temperature to allow complex formation. In the meantime, complete medium was 
aspirated, cells were gently washed with 1xPBS and 2.5ml of transfection 
medium was added, which did not contain Penicillin/Streptomycin. The culture 
was incubated at 37°C/5% CO2 for 4h and subsequently the medium was 
aspirated and exchanged for complete growth medium. The transfected cells 
were then incubated until reaching 80-90% confluence (24h) and then passaged 
into a 10cm dish. After another 24h, the selective medium was added containing 
the sufficient concentration of 500µg/ml G418, which beforehand was assessed 
to kill non-resistant cells.  
After densely packed colonies had formed they were isolated with cloning 
cylinders (polymer: Corning; glass: ZITT-THOMA GmbH Laborbedarf und 
Glasbläserei, Freiburg). Therefore, the position of the selected colonies was 
marked with a waterproof pen on the bottom of the dish under the light 
microscope, medium was aspirated, the bottom edge of a cloning cylinder was 
dipped into high vacuum grease (Corning) and placed as such to enclose and 
seal the area where the colony was situated. Thereby, it was crucial that neither 
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any of the grease infiltrated the enclosed area of the cylinder where the colony 
was located nor that there was an insufficient amount of grease which would 
cause a leaking of any of the 100µl 1xTrypsin-EDTA which was added 
immediately after placement of the cylinder. After that procedure had been 
conducted with all clones to be grown, the plate was incubated at 37°C/5% CO2 
for 4min. Then, 200µl of complete medium w/o antibiotics were added and the 
liquid was resuspended within the cylinder. The suspension was put into a well of 
a 12-well-plate containing 1ml of complete medium w/o antibiotics which was 
swirled gently after adding the cell suspension. Selective medium was added 
after 24h and when those cultures reached 70-80% confluence the cells were 
passaged into 6-well-plates and consequently after expansion finally into 10cm 
dishes. From there, back up freezes were done applying the procedure described 
in 6.2.1. The screening for the Tet-On 3G transactivator protein was performed in 
terms of protein expression and its potential to induce transgene expression 
(6.3.1). 
6.2.2.2 Stable cell lines for inducible expression of wild type Ubc9 
The TetA cells were then used to generate double positive cell lines constitutively 
expressing the transactivator as well as conditionally the Ubc9 transgene 
downstream of the TetR-responsive promoter. Again, Polyfect was used with the 
same protocol as described before for the transactivator except for some 
amendments. 
Before that transfection was carried out, the concentration of Hygromycin B was 
assessed in non-transfected NIH 3T3-TetA cells. Thereby, the required lethal 
dose of that antibiotic was found to kill all non-resistant cells. The transfection 
was again performed in 6-well plates, a concentration of 2.5µg of pTre3G-Ubc9 
plasmid was used, diluted with 150µl of DMEM and mixed with 15µl Polyfect. As 
there was no resistance gene present on the pTre3G-Ubc9 plasmid a linear 
selection marker had to be cotransfected in a concentration of 50ng per 1µg of 
plasmid DNA. The Hygromycin resistance gene was governed by a SV40 
promoter and flanked by a SV40 polyadenylation signal at the 3’ end. The 
transfection procedure was conducted equally as already described above. The 
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cloning of Ubc9 into the multiple cloning site of the pTre3G plasmid was done by 
the former lab member Yvonne Steuernagel. 
For the selection of colonies, the 6-well was split in four 10cm dishes 24h post 
transfection, after a recovery time of 48h 150µg/ml Hygromycin B (stock 
50mg/ml, Clontech) was added to the medium. After colony formation for about 
12 days, many resistant large colonies had been formed, whereas a control 
culture dish without the linear Hygromycin resistancy marker suffered from 90% 
or more cell death. Subsequently, colonies were picked applying the same 
procedure as described before (6.2.2.1) and grown up in wells of a 24 well plate 
(Costar). After being split for the first time, one third of the cells was passaged on 
in another 24well and the other two thirds were spun down again and genotyped 
(6.4.1) 
6.2.3 Knock down of Ubc9 Transient knock down of Ubc9 with siRNA 
Seeding of NIH 3T3 cells was performed in accordingly selected plates one day 
prior to transfection to obtain 30-40% confluence at transfection. For the 
transfection, a pool of three siRNAs (Thermo Scientific) was used routinely. 
Sequences were chosen as such that all of them were specifically targeting 
different regions of the longest of three murine transcript variants of Ubc9 
identified at NCBI Nucleotide database entry NM_001177609.1. The sequences 
were the following: 
siRNA 1: CACUGGCAUAUUCAGUCUUUU  
siRNA 2: CCAGAAAGGUGAAAGACUGUU 
siRNA 3: CUGUGAUCUUAGGGCUUACUU 
Each siRNA was re-suspended to 40µM diltions in nuclease-free water, aliquoted 
and stored in several working stocks at -20°C. Major stocks were preserved at -
80°C. For the transfection, 1.5µl of each siRNA and 5µl of Lipofectamine RNAi 
max (Invitrogen) were used per well of a 6-well plate. As control, there was 
always 4.5µl of a non-targeting scrambled siRNA-pool of the same concentration 
tested in a separate culture well. The transfection reagent as well as the siRNAs 
were diluted in total volumes of 250µl of OptiMEM (Gibco), mixed by pipetting up 
and down at least 20 times, spun down briefly, pooled, mixed again and 
incubated for 30min at room temperature. In the meantime, the complete growth 
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medium was aspirated, cultures were washed with 1xPBS, and 2.5ml of complete 
medium w/o antibiotics (refer to 6.2.2.1) was added. Then the transfection mix 
was added slowly, plates were swirled and incubated for the indicated time 
points, normally for 48h. The ratio between the transfection mix and the medium 
was always kept constant irrespective of the medium volume used. 
6.2.4 Transient overexpression of wild type Ubc9 
6.2.4.1 Testing the pTre3G-gene of interest expression in NIH 3T3 Tet-On cells 
Overexpression of Ubc9 was done transiently in NIH 3T3 TetA clone 7 cells. 
Therefore the Fugene reagent (Promega) was used in a ratio of 4µl of Fugene 
per 1µg of DNA for 48h which had been found to yield the best transfection 
efficiency in NIH 3T3 cells114. The protocol was calculated using the Fugene HD 
database, which aimed to give an optimal protocol in terms of cell seeding 
number, amount of DNA and the volume of Fugene reagent115. However, multiple 
steps of the protocol were modified. The cell numbers recommended by the 
database were found to lead to very confluent cultures after 48h, so they were 
lowered as following. For 6-well plates, the protocol database recommended to 
seed 2.5x105 cells per well, but only 1.5-2x105 cells were seeded, for the histone 
extraction, only 1x106 instead of 3x106 cells per 10cm dish were seeded. As the 
medium suggestions were also rather high only the halves of the proposed media 
volumes were taken per culture dish or well. Hence, for the calculation of the 
DNA and the Fugene reagent the number of wells was reduced by half to keep 
the ratio of medium to DNA-Fugene-complexes constant. The DNA was diluted in 
OptiMEM to a concentration of 0.020µg/µl, the indicated Fugene reagent was 
added, the solution was mixed by resuspending cautiously 30 times, spun down 
briefly and then incubated for complex formation at room temperature for 30min. 
Then, complete medium w/o antibiotics was added to the transfection mix, cells 
were washed with 1xPBS, and the transfection medium containing the pTre3G-
Ubc9 plasmid was added to the cells. The medium containing the transfection 
complexes was then left in the culture vessel until analysis, as the Fugene 
reagent does not demand a medium exchange. 
In order to have a rough estimation of the transfection efficiency, a pCruz-eGFP 
construct was transfected in a separate well using the same conditions. This well 
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was then evaluated for GFP expression before the protein lysates were prepared 
from the other cells. The pCruz-eGFP was provided by the lab technician 
Stefanie Koidl. 
6.3 Characterization of stable clones 
The previous section explained how the cells were treated. After that, clones 
which had grown up and had managed to survive the stringent antibiotic selection 
processes, their ability to stably express the protein of interest was evaluated by 
different means. Thereby, according to the protein analyzed, different approaches 
were applied. 
6.3.1 Tet-On 3G transactivator screening in stable clones 
First, the TetA expression level was evaluated by immunoblotting. Second, a 
functional reporter gene assay was run to test the efficiency of the TetA to induce 
the reporter gene. 
6.3.1.1 Tet-On 3G transactivator protein expression screen by immunoblotting 
As an initial screen, the protein expression of the Tet transactivator in the 
absence and the presence of Doxycycline were analysed. Each of the seven 
clones that were picked and grown up was seeded in 6cm cell culture dishes (BD 
Falcon) at a density of approximately 2x105 cells. 2.5ml of Induction medium 
[DMEM (Sigma Aldrich) supplemented with 10% Tetracycline-free FBS 
(Clontech), 1x Glutamax (Gibco, 100x stock), 1xPenecillin/Streptomycin (Sigma 
Aldrich, 100x stock) and 1x Non-essential Amino acids (Sigma Aldrich, 100x 
stock) was added per well. That medium either contained or did not contain 
1µg/ml Doxycycline. The seeded cell density was sufficient to yield a 60-70% 
confluence after 48h. As negative control, non-transfected NIH 3T3 cells were 
also seeded in the same media either devoid of or containing 1µg/ml 
Doxycycline. As positive control a previously identified transactivator protein 
expressing NIH 3T3 cell line passage 20 was re-evaluated. 
48h after the seeding and the therewith accompanied induction, whole cell 
lysates were prepared (6.5.1) and 20µg of total protein were applied to a 12.5% 
SDS PAGE gel. For SDS PAGE and the Western blot procedures refer to 6.5.2-
6.5.3.1. 
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The primary antibody was a monoclonal TetR mouse antibody (Clontech) stored 
at -20°C and thawed and kept on ice throughout its usage. For the 
immunodetection the antibody was diluted 1:500 in 5% (w/v) milk in PBST (0.05% 
(v/v) 20% Tween-20) and incubated at room temperature with slow agitation for 
2h. The antibody was suited to detect both the transactivator as well as the 
transrepressor. 
The secondary antibody against mouse (Sigma) was diluted 1:2500 in 5ml of 
50g/l non fat dry milk powder in PBST (0.05% (v/v) 20% Tween-20). Further 
details for the immunoblot detection are specified in 6.5.3.1. 
6.3.1.2 Functional Dual Luciferase Assay 
To find out whether the transactivator is able to bind to the Tet-resposive 
promoter and to activate target gene transcription, a dual Luciferase assay was 
carried out. The candidate NIH 3T3 TetA clone cultures were seeded at a density 
of 8x104 cells per well of a 12 well plate one day before transfection. The next 
morning, cells were transiently co-transfected with 1µg per well of a commercial 
pTre3G-Luciferase plasmid (Clontech) and 20ng of pLG4.70-synthetic Renilla 
Luciferase gene plasmid (Promega) using 10µl of Polyfect reagent, which were 
added to 100µl DMEM. The detailed transfection procedure is delineated in 
6.2.2.1. All clones were transfected in triplets for the uninduced, as well as for the 
induced condition. 
The medium containing the transfection complexes was exchanged for induction 
medium either being devoid of or containing 1µg/ml or 3µg/ml Doxycycline and 
incubated for 24h. 
For the detection of Luciferase activity the Dual-Luciferase® Assay Reporter 
System (Promega) was used in a modified protocol. The cells were lysed by 
adding 100µl of ice cold 1x cell lysis buffer (stock 5x) from the kit diluted with 
mQH2O, slowly agitating the plate for 5min, scraping the cell slurry and after 
transferring it to a Eppendorf tube spinning it down at 4°C and maximum speed 
for 20min. The supernatant was transferred to a new tube and stored on ice. If 
the protocol was not continued the same day lysates were frozen at -20°C for 
short term or at -80°C for long term storage. 
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Table 1: Luciferase dual measurement 
Injector I 
50µl LARII reagent injected 
2s delay 
10s measurement Firefly Luciferase 
Injector II 
50µl Stop & Glo®-Reagent-Renilla 
substrate injected 
2s delay 
10s measurement Renilla Luciferase 
 
The protocol was continued by applying 20µl of each lysate in triplicates to a 
white, flat bottom 96-well plate (Nunc) which was kept on ice. The Dual luciferase 
assay was further conducted according to the manufacturers’ instructions with the 
following amendment: the Luciferase Assay Reagent II (LARII) and the Stop & 
Glo® Buffer were diluted 1:1 with mQH2O. Then, the samples were measured in 
a plate reader (Berthold) by injecting first the Firefly substrate contained in the 
LARII buffer and then the quencher with the Renilla substrate contained in the 
Stop & Glo® buffer by a sequential program ( 
 
Table 1). By dividing the Firefly readout through the Renilla readout the samples 
were normalized, by dividing each value through the measured value of the 
negative control the measurement was normalized against the blank. In multiple 
experiments means, standard deviations and student t-test were used to evaluate 
the significance of the data in Microsoft EXCEL. 
6.4 Characterization of inducible Ubc9 overexpression cell clones 
6.4.1 Genotyping PCR 
PCR was used as an initial screen in order to rule out false positive stable clones, 
which were stably expressing the Hygromycin resistance gene, even though 
having not integrated the pTre3G plasmid into their genome. Rather than testing 
all clones for protein expression genotyping considerably reduced the number of 
clones which had to be scaled up and maintained.  
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Therefore, clone cultures originating from Hygromycin-resistant colonies were 
expanded in wells of a 24-well plate and split at the ratio of 1:3 when they had 
reached a minimum confluence of 60%. One third was passaged into a new 24-
well plate and the other two thirds were genotyped as following. 
6.4.1.1 DNA Isolation 
For the DNA isolation, a crude extraction protocol was used. Two thirds of the cell 
mass of the clones in suspension from a 24 well plate were spun down at the 
same conditions applied for the cell culture. After the supernatant had been 
aspirated 50µl of lysis buffer [1xPCR buffer (Quiagen), 200µl/ml TritonX, 
100µg/ml Proteinase K (Thermo Scientific - Fermentas), mQH2O] were added to 
the pellet, resuspended and transferred to an Eppendorf tube. Then, the 
digestion was done at 55°C in a waterbath for 4h. After that, the proteinase K was 
inactivated by heating the sample at 65°C for 30min. Then, the lysate was spun 
down at maximum speed for 10min and the supernatant was transferred to a 
fresh tube. 100µl of isopropanol was added, briefly mixed by resuspending and 
incubated at room temperature for 5min. Furthermore the samples were spun 
down at maximum speed for 15min, the supernatant was removed, 70% EtOH 
was added and tubes were tabbed, spun down for 5min again, pellets were dried 
by inverting the tubes as long as pellets became transparent (approximately 
10min). After that, 30µl of TE buffer preheated to 60°C were added and pellets 
were resuspended therein. Each sample was measured in the Nanodrop and if 
the DNA concentration was above 500ng/µl the concentration was adjusted to 
that threshold. 
6.4.1.2 PCR program 
After the DNA concentrations had been approximated to 500ng/µl with nuclease-
free H2O, 2µl of each sample were pipetted into an emtpy vial of a PCR tube-strip 
(Thermo Scientific). All master mix reagents were thawed, briefly vortexed and 
kept on ice throughout their use. The master mix was prepared according to 
Table 2: Master mix per sample. As negative control the DNA of NIH 3T3 Tet-on 
cells was used; the master mix control was 2µl of nuclease free H2O as template 
instead of sample DNA whereas the positive control was 10ng of pTre3G-wt-
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Ubc9 plasmid DNA. The forward primer was designed to bind to the vector within 
the promoter region and the reverse primer was homologous to the 3’end of the 
inserted, transgenic hUbc9 gene ( 
Table 3). 
Table 2: Master mix per sample 
Reagent Volume [µl] 
Nuclease-free H2O (Quiagen) 17 
pTre3G forward primer (Eurofins MWG Operon) 0.1 
Ubc9 reverse primer (Eurofins MWG Operon) 0.1 
dNTPs 0.5 
Crimson LongAmp® Taq Polymerase buffer (New England 
Biolabs Inc.) 5 
Crimson LongAmp® Taq Polymerase (New England Biolabs 
Inc.) 0.25 
 
Table 3: Primer sequences for genotyping 
Primer Sequence 5’ -> 3’ 
pTre3Gforward primer GTGAACCGTCAGATCGCCTGGAGC 
hUbc9 reverse primer TACATTGGATCCTTATGAGGGCGCAAACTTCTTGGC
 
Table 4: PCR cycle program 
The PCR tube strips were closed, drops 
sticking to the walls of the tubes were spun 
down by a short centrifugation step and tubes 
were put into the thermo cycler (DNA Engine 
Peltier Thermal Cycler, Biorad) pre-heated to 
94°C. The genotyping program was then run in 
30 cycles (cycle steps 2-5 in  
Table 4: PCR cycle program). 
 
1% (w/v) Agarose gel solution in TAE 
buffer was prepared by weighing 4g of Agarose (Lonza), adding 400ml of 1xTAE 
buffer (diluted from 50x stock solution: 2M Tris, 5.7% (v/v) acetic acid, 0.05M 
EDTA pH 8.0, pH adjusted with HCl to pH 7.7) and boiling it in the microwave 
Step Temp [°C] Time 
1 94 5min 
2 94 20s 
3 55 30s 
4 65 40s 
5 Go to step 2 30-times 
6 65 7min 
7 8 for ever 
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until the Agarose dissolved completely and 1:10000 dilution of Gel red (Biotium) 
were added. Air bubbles were avoided during polymerization at room 
temperature.  
After polymerization, the gel was submerged in 1xTAE buffer. 5µl of 1kb DNA 
ladder and 10µl of the amplified samples and controls were loaded next to each 
other. The gels were run at constant voltage (Electrophoresis power pack EPS 
601, GE Healthcare) depending on the gel size between 100V and 200V for 
25min to 45min. 
Pictures were taken in the UV transilluminator after the gel had been positioned 
directly onto the illuminator surface and focus and exposure time had been 
adjusted by previewing the saturation of the signal. 
6.5 Western Blot 
The immunoblot is the most frequently applied technique to analyze the 
expression level of specific proteins. First, the content of the TetA and Ubc9 in 
cell lysates was determined using specific monoclonal and polyclonal antibodies, 
respectively. Second, the Histone extracts from Ubc9 knock down cells were 
evaluated. Moreover, the coomassie staining of SDS PAGE gels was used to 
determine concentrations and the purity of proteins. 
6.5.1 Protein preparation of whole cell lysates 
For the analysis of whole cell protein lysates from cultivated cells, they were 
washed once with cold 1xPBS. Then, 95°C-heated 2x SDS-Laemmli buffer 
(100mM Tris pH 6.8, 4% SDS, 20% Glycerin, dH2O) was added directly to the 
cells and distributed by rapidly swirling the plate. After that a cell scraper (1.8cm 
blade, Costar) was used to collect the cell suspension and transfer it to an 
Eppendorf tube. Then, the tubes were sonicated (Diagenode Bioruptor) for 5min 
at cycles of 15s high level pulse and a 15s intermission. That was done to break 
up all cellular compartments and to shear the DNA in order to get a 
homogeneous sample. After sonication, the cell lysates were heated for 1min and 
then spun down briefly. 
In order to load comparable protein amounts in the SDS PAGE later on, a protein 
estimation was performed. Therefore, 10µl of each lysate were pipetted in a clear 
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flat bottom 96-well plate (Nunc) in duplicates. Then, the reagents of the BCA kit 
(Thermo Scientific) were mixed in 1:50 ratio and 200µl were added to each well. 
After incubation at 37°C for 30min (Thermo Scientific Heraeus Function line), the 
plate was cooled down to room temperature again and the absorbance at 562nm 
was measured. Initially, equations of multiple standard curves were calculated by 
assaying a BSA standard (contained in the kit). The sample concentration was 
afterwards determined in the same way by the comparison to a mean standard 
equation. After adding the adequate sample volumes sufficient for the required 
protein content, the volumes were equalized using 2x SDS-Laemmli buffer 
supplemented with 0.2% (w/v) Bromophenol blue and 200mM freshly added DTT. 
6.5.2 Sodium dodecyl sulfate polyacrylamide gel electrophoresis 
Sodium dodecyl-sulfate polyacrylamide-gel-electrophoresis was used either for 
preparative reasons in the immunoblot protocol. Alternatively, instead of 
preparative gels, also analytical gels were used, which were then coomassie 
stained. 
6.5.2.1 Preparation of denaturing polyacrylamide gels 
Table 5: Formulae of SDS PAGE separation gels of different percentages 
Reagent Gel percentage 
 4% (staking) 12.5% 20% 
mQH2O 42.9ml 25.5ml 7.9ml 
2M Tris pH 8.8 14ml 14ml 14ml 
30% Acrylamide:Bis 30:0.8 (Roth) 11.7ml 29.2ml 46.7ml 
20% SDS 350µl 350µl 350µl 
Mix well 
10% APS 700µl 700µl 700µl 
TEMED 70µl 70µl 70µl 
 
In general, two different gel types were used. For separation of Ubc9, 12.5% 
Polyacrylamide gels were used cast in a 10 gel stack: alumina support plates, 
glass plates (both 10cmx8cm, GE Healthcare) and spacers (GE Healthcare) were 
cleaned with 70% Ethanol and then with mQH2O with fibre-free tissue paper 
(Kimberly-Clark professional) to remove any gel residues. Self-designed casting 
trays were cleaned as well and components were assembled as following: a 
Page 49 of 82 
 
transparent plastic foil at the very bottom of the tray, a alumina plate, spacers at 
the side edges and a glass plate on top, then a alumina plate again and so on. 
This was done 10 times, after the last glass plate again a plastic foil was placed 
and the casting tray was closed tightly with screw clamps. 12.5% gel solution was 
mixed according to the formula (Table 5: Formulae of SDS PAGE separation gels 
of different percentages) under the fume hood using a magnetic stirrer, finally 
10% APS and TEMED were added, mixed well and then the solution was poured 
in the middle of the casting tray until an appropriate height for the separation gel 
was reached. The tray was positioned in a diagonal angle to ensure equal levels 
for the separation gel, put back into a horizontal position and then every gel was 
covered with isopropanol and let polymerize for 1h. Residual isopropanol was 
removed by inversion of the cast tray, rinsing the gel with 0.5M Tris pH 6.8 and 
drying remaining liquid in the corners with chromatography paper.  
The stacking gel was a 4% polyacrylamide gel by default: 22.7ml mQH2O, 3ml 
0.5M Tris pH 6.8, 4ml 30:0.8 Acrylamide:Bis, 150µl 20% SDS (w/v), mixed in the 
fume hood on a magnetic stirrer, 150µl 10% APS and 30µl TEMED were added, 
mixed and poured on top of the separation gel. Immediately, 12 slot-gel combs 
were rapidly inserted into every gel and again it was given 1h for polymerization. 
After that, the casting tray was cautiously opened, the gel stack was taken out by 
pulling the plastic sheet behind the bottom gel, gels were laid on plastic foil which 
had been topped with H2O-wettened paper towels, and the gel stack was 
wrapped therein and stored at 4°C until use. 
The separation of histones required a higher resolution and thus gradient gels 
were the formulation of choice. To pour gradient gels, a more elaborate 
procedure was demanded. The alumina supports as well as the glass plates were 
larger (10cmx12cm, GE Healthcare). The same was true in regard of the size of 
the casting tray and moreover it had an inlet opening at the rear bottom. The 
separation gel 5% as well as 20% gel solutions (Table 5) were prepared 
separately in 50ml Falcon tubes. The assembled casting tray as described before 
was connected via a clamped tube to the outlet of the mixing unit resting on a 
magnetic stirring plate and consisting of two by a cylinders being interconnected. 
In the first outlet cylinder contained a stirring bar and was directly connected to 
the casting tray. That first cylinder was filled first with the 5% gel. Then, the clamp 
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blocking the interconnecting tube was loosened and the 5% was let into tube until 
entering the second cylinder to remove any air out of the system. Immediately, 
the clamp was closed again, the 20% gel solution was poured into the second 
cylinder, the 5% gel was again leveled to an equal amount, then the 
interconnection was opened first followed by opening the tube connecting the 
mixing unit and the cast tray. The 20% gel entered the 5% cylinder through the 
connecting tube; the solutions were mixed by the stirring bar and entered the 
casting tray filling it from the bottom. When the desired height of the separation 
gel was reached, the clamp of the tube connecting the casting tray with the 
mixing cylinders was closed, the single gel solutions were again leveled, covered 
with isopropanol and let polymerize for 1h.  
For the stacking gel the formula stated in Table 5: Formulae of SDS PAGE 
separation gels of different percentages and the same procedure as described for 
the separation gel were conducted. After pouring the gel into the casting tray, the 
gel combs were inserted. 
6.5.2.2 Resolution of proteins by SDS PAGE 
Depending on the sample and its protein concentration, sample volumes between 
10µl and 40µl were applied to a lane of the gel. In the outermost left lane 4µl of a 
pre-stained protein standard ladder (Fermentas) and outermost right 8µl of an 
unstained protein standard (Fermentas) ladder were loaded by default. Every 
sample contained 2x Laemmli buffer containing 0.02% (w/v) bromophenol blue 
and supplemented with 250mM fresh DTT. All gels were run in SDS PAGE 
chambers (ELPHO “V100”, GE Healthcare) filled with running buffer (25mM Tris, 
192mM Glycine, 0.05% SDS (w/v), in mQH2O) at 25mA constant current 
(Electrophoresis power pack EPS 601, GE Healthcare) per gel as long as the 
bromophenol blue front started to elute at the bottom or before the 10kDa band of 
the pre-stained protein standard ladder reached the very bottom. 
6.5.3 Semi-dry Western Blot 
The specific detection of a particular protein was only achieved after the transfer 
of all proteins from the gel to a nitrocellulose membrane. Therefore, a cut piece of 
Whatman paper (GB005, Whatman) topped with the membrane (Protan® 
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Nitrocellulose Transfer membrane, Whatman) was soaked and activated in 
transfer Buffer [25mM Tris, 193mM Glycine (from a 10x stock solution), 20% (v/v) 
Methanol and 1.8ml of 20% (w/v) SDS added freshly, mQH2O  up to 1l]. The gel 
spacers and the glass plate were removed with a razor blade and the stacking 
gel was cut off and discarded. In contrast, the separation gel was placed on top 
of the activated membrane, and another Whatman paper was placed on top of 
the gel and soaked in the Transfer Buffer as well. Then that sandwich was taken 
out of the buffer, pressed in between two layers of paper towel. Finally, it was 
placed onto the blotting apparatus (Peqlab) in the same orientation as it was 
assembled. The sandwich was rolled two times to remove any air bubbles; any 
excessive buffer on the electrode was dried with paper towels, the lid of the 
blotter was placed on top and screws were equally tightened. The blotting 
apparatus was connected to the power supply (Power Pac® HC Power Supply 
305300, BioRad) which was set to 100mA per small membrane for 1h. When 
there was only one sandwich in the blotter, the current was increased from 
150mA to 250mA for 1h. Otherwise the voltage for the transfer would have been 
to low resulting in incomplete blotting. For the larger gradient gels the applied 
conditions were at least 200mA for 1h. 
After the blotting procedure was  finished, the blotted membranes were either left 
in the blotting apparatus over night or stained with 0.5% (w/v) Ponceau S (Sigma 
Aldrich) solution (in 1% acetic acid) for approximately 5min and then destained 
using 1% (v/v) acetic acid or dH2O. The unstained protein ladder bands were 
indicated using a pen, edges were cut and the membranes were scanned (Epson 
500 Series). This was done to evaluate the correct transfer of proteins and to 
evaluate any imbalances in the protein contents of the individual sample lanes. 
Furthermore, the staining was removed in PBS Tween-20 (Tween concentration 
range from 0.05%-0.2% (v/v) - depending on the primary antibody used) and then 
blocked in 5% (w/v) non-fat dried milk (Milk powder blotting grade, Roth) in 
PBST, either at room temperature with agitation for 1h or at 4°C with agitation 
over night. 
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6.5.3.1 Antibody detection 
The membranes were incubated with primary antibodies diluted depending on the 
antibody and the sample, in 5% (w/v) milk in PBST at room temperature with slow 
agitation for 1-2h. After that the membrane was once rinsed with PBST and then 
washed at least 3 times with PBST with faster, orbital shaking for 10min each 
time. 
The secondary antibody was applied according to the species the primary 
antibody was raised in. However, all of them were from Jackson Immuno 
Research, coupled to Horse Reddish Peroxidase (HRP) and diluted in 5% (w/v) 
milk PBST 1:2500 to 1:5000 depending on the primary antibody. The incubation 
of the secondary antibodies was always carried out at room temperature with 
slow agitation for 1h. 
Table 6: Antibodies for immunoblotting 
Antibody Diluton(s) Species Source 
Ubc9 1:1000 rabbit homemade 
Ubc9 1:1000-1:4000 goat homemade 
TetR 1:500 mouse Clontech 
H3 1:3000 rabbit Upstate 
H3K9me1 1:1000 rabbit Thomas Jenuwein 
H3K9me2 1:1000 rabbit Thomas Jenuwein 
H3K9me3 1:1000 rabbit Thomas Jenuwein 
H3K27me1 1:1000 rabbit Thomas Jenuwein 
H3K27me2 1:1000 rabbit Thomas Jenuwein 
H3K27me3 1:1000 rabbit Thomas Jenuwein 
H4K20me1 1:1000 rabbit Thomas Jenuwein 
H4K20me2 1:1000 rabbit Thomas Jenuwein 
H4K20me3 1:1000 rabbit Thomas Jenuwein 
beta-tubulin 1:2500 rabbit Santa Cruz 
rabbit-HRP 1:5000  Jackson Immuno 
Research 
goat-HRP 1:5000  Jackson Immuno 
Research 
mouse-HRP 1:5000  Jackson Immuno 
Research 
 
Page 53 of 82 
 
After the secondary antibody incubation the membrane was again washed for 
three times applying the same conditions as before. In the meantime, the ECL 
reagent (Thermo Scientific) which contains the substrate for the horseradish 
peroxidase was prepared. Therefore, the two reagents contained in the kit were 
mixed 1:1. When Super-ECL was used, the two reagents of that kit were mixed 
1:1 and then diluted in ECL or PBS to a final concentration from 10 to 50% 
(v/v).The washing solution was drained from the membrane by gravity and then 
the membrane was placed horizontally. The ECL reagent was slowly applied to 
the surface of the membrane until it was covered completely. Then it was 
incubated for 1.5min and then the membrane was rinsed with the reagent for 
another 3min. After that the membrane was put in between of two plastic sheets 
fixed in a light tight developing cassette. The membrane was exposed to an x-ray 
film (GE Healthcare) in the dark room for different time spans ranging from 1s to 
10min. After that the film was developed in the Kodak M35 B x-ray film developer. 
6.6 Histone modification analysis 
The techniques for the evaluation of histone methylation were a histone acid 
extraction from Ubc9 knock down cells, followed by immunoblotting and further 
the immunofluorescent staining of Histones in knock down cells.  
6.6.1 Histone acid extraction of 3T3 Ubc9 knock down 
The extraction was done according to the adapted Histone acid extraction 
protocol provided by Abcam116. For analysis, Ubc9 knock down cells were 
prepared as detailed in 6.2.3 and immunoblot was done as described in 6.5.1. 
Two dishes were prepared for each sample, one for the histone acid extraction 
and one to follow the Ubc9 expression pattern from total cell lysates. For the 
preparation of histone acid extracts, each plate was washed twice with ice cold 
1xPBS. Then 1ml of Triton extraction buffer was added (TEB: 0.5% Triton-X 100 
(v/v), 2mM phenylmethylsulfonyl fluoride, 0.02% (v/v) NaAz in 1xPBS) and plates 
were put on ice on the shaker to enable cell lysis for 10min. After that, the lysate 
was scraped off the cell culture dishes and transferred to Eppendorf tubes. The 
nuclei were spun down at 6400g and 4°C for 11min and the supernatant was 
removed. Then, 0.5ml of TEB was added and tubes were flicked to wash the 
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pellets. Next, the tubes were spun down again applying the conditions as before. 
The supernatant was removed and the pellets were resuspended in 250µl of 0.2N 
hydrochloric acid (Merck, prepared from 37% (v/v) stock) and histones were 
extracted by end over end shaking at 4°C over night. The next day, the debris 
was centrifuged at the same conditions as mentioned above and the supernatant 
was transferred to a fresh tube which was stored on ice. 
The purity and the concentration of the extracted histones were determined on 
coomassie stained SDS gradient gels by comparison to a α-lactalbumin standard. 
Therefore, all extracts were loaded onto an SDS gel applying different volumes 
and comparing them to the α-lactalbumin standard of known concentration. The 
staining procedure of gels was started by fixing them in 40% (v/v) Ethanol in 10% 
(v/v) acetic acid shaking at room temperature for 10min. Then, the Coomassie 
staining solution was added and either left shaking at room temperature for 3h or 
for a quick-stain it was heated in the microwave for 30s. Then, it was given time 
to cool down for 1min followed by heating it for another 15s. Then, the gels were 
left on the shaker for another 10min to an hour and after that destained. The 
destaining solution was 1% (v/v) acetic acid. For destaining, the solution was 
exchanged every 2-4 hours. Destaining was ultimately either done over night or 
also with a quick microwave protocol by heating the gels in destaining solution for 
30s. Then, it was shaken at room temperature for 30min, exchanging the 
destaining solution and let therein until concentration evaluation on the white light 
transilluminator or drying it. 
For the gel drying procedure, gels were rinsed with distilled water, put on a wet 
Chromatography paper (Munktell), covered with a transparent plastic foil and laid 
on the vacuum heating plate (Biometra). Then, the vacuum pump (Eppendorf 
concentrator 5301) was switched on. A plastic cover enclosed the gels by the 
formed vacuum and then 60°C were applied for 2h. 
Extracts were always as pure as figures shown by Shechter et. al and that 
publication was used to determine the single Histone bands and their 
concentrations. 117 
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6.7 Ubc9 Antibody Affinity Purification and Characterization 
6.7.1 Expression and purification of recombinant human Ubc9 
The purification of recombinant, untagged human Ubc9 was performed for the 
serum affinity chromatography purification of Ubc9-specific goat antibodies, 
which required Ubc9. 
BL21 gold bacteria, a competent protein expression strain, were heat shock 
transformed with a pET23a-hUbc9 plasmid construct according to the procedure 
described before (6.1.1). The plating on one Petri dish was done only for back up 
purposes in that case. Instead of growing resistant colonies the culture was 
directly grown up in 5ml LB medium containing 100µg/ml Ampicillin for 8h. After 
that, the whole culture was scaled up to 100ml LB medium containing 100µg/ml 
Amp and grown at 37°C with 200rpm shaking over night. The next morning, that 
culture was scaled up to 4l adding 25ml of the overnight culture to 1l of LB/Amp 
medium in a 2l Erlenmeyer flask and incubating the culture again at 37°C, 
170rpm shaking  (New Brunswick Scientific innova 40) until it reached an OD600 
of 0.65 (Eppendorf Biophotometer plus). A sample of the non-induced culture 
was taken. Then, 1mM of IPTG was added to each liter of culture to induce the 
protein expression and incubated at 37°C for 4h. Then, the culture was harvested 
by spinning them in 6 250ml centrifuge buckets at 104g for 20min, 4°C (Sorvall 
RC 6 plus, rotor: PTI F10S-6x500y), the supernatants were discarded. Having the 
pellets from multiple spins enriched at one side of the containers they were then 
resuspended in a total volume of 45ml ice cold lysis buffer (25mM Na3HPO4, 
50mM NaCl, 0.1mM PMSF, 1mM DTT, 1µg/ml Aprotinin, 1µg/ml 
Leupeptin/Pepstatin). The protease inhibitors and DTT were added freshly just 
before resuspending the pellets. After that, the homogeneous lysates were 
divided in three 50ml Falcon tubes containing equal volumes, snap frozen in 
liquid nitrogen and stored at -80°C over night. 
The next day the lysates were thawed on ice and then sonicated on ice 3 times at 
90% intensity for 10s each time with 20s breaks in between. Then, the lysate was 
filled into ultracentrifuge tubes, which were balanced and spun at 105g, 4°C for 
1h.  
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For the ion exchange chromatography, 5ml of SP Sepharose beads (GE 
Healthcare) were packed into a column and equilibrated with 10 column volumes 
(50ml) of lysis buffer. The supernatant of the ultracentrifugation was collected and 
passed through the beads for 3 times, each time washing the column with 5 
column volumes (25ml) of lysis buffer in between. To elute the bound protein 
from the ion exchange resin 10 times 2ml of elution buffer (25mM Na3HPO4, 
300mM NaCl 1mM DTT, 1µg/ml Aprotinin, 1µg/ml Leupeptin/Pepstatin) were 
added and 2ml fractions were collected. Then, the fractions were tested for their 
protein content by applying 1µl of each fraction to a strip of nitrocellulose 
membrane and staining that with 0.5% (w/v) Ponceau S followed by destaining 
with 1% (v/v) acetic acid. The protein containing elution fractions were pooled 
and concentrated using protein concentrators (Vivaspin, Santorius) with a 
molecular weight cut off of 10kDa at 1500g  (maximum speed) as long as a 
volume of just below 5ml was obtained. 
Then, the concentrated sample was injected to an ÄKTA tm purifier 10 FPLC 
system with UC 900 (GE Healthcare) consisting out of pHIC-900, UV-900, P-900, 
Frac-150 and connected to the Hiload 26/60 S200 Superdex prep grade size 
exclusion column which had been equilibrated before. For that the system and 
the column were rinsed with 318ml of degased (sonication: 2x8min 90% 
continuous with 10min break) transport buffer (100mM NaCl, 20mM Tris-HCl 
pH8.0) at a maximum (alarm) pressure of 0.65MPa (0.5MPa column pressure + 
~0.15MPa system pressure) and a flow rate of 2ml/min. 
For running of the sample the same conditions were applied and 36 fractions of 
5ml were collected starting from 200ml after eluting the column void volume of 
approximately 318ml. 
10µl of the fractions containing the highest protein content including the 
proximate fractions were diluted with 40µl of 2xLaemmli containing 200mM DTT, 
were run on an SDS-PAGE gel and coomassie stained by the described methods 
(6.5.2, 6.6.1). One fraction contained the highest protein content, whereas the 
previous and the subsequent ones also contained some protein. So, the highly 
concentrated fraction was divided in 1ml aliquots whereas the less concentrated 
fractions were pooled and split in 2ml aliquots. Small aliquots were taken for 
concentration determination on a SDS-PAGE gel by the previously described 
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method (6.5.2, 6.6.1). Then, the aliquots were snap frozen in liquid nitrogen and 
stored at -80°C. 
6.7.2 Affinity chromatography of crude Ubc9 goat serum 
The first step was to dialyse 1mg of purified recombinant Ubc9 into the adequate 
carbonate buffer [0.2M NaHCO3 (Merck), 0.2M Na2CO3 (Riedel del Haën) in the 
ratio 10:1, pH 8.8] for the affinity chromatography. A dialysis cassette with a 
membrane cut off of 10kDa was equilibrated in ice cold carbonate buffer with 
slow agitation at 4°C. Then, 1mg of Ubc9 in transport buffer was cautiously 
injected into the cassette using a 1ml syringe, the cassette was put into at least 
500ml of carbonate buffer and dialysed for at 4°C for approximately 4h. After that, 
the carbonate buffer was exchanged and dialysis was continued at 4°C, slow 
agitation over night. The next morning, again the buffer was exchanged and 
dialysis was continued for another 2h applying the same conditions. 
Cyanogen bromide-activated Sepharose® (Sigma Aldrich) beads stored at 4°C 
were equilibrated to room temperature, 800mg were weighed and swollen in 10ml 
of 1mM HCl (37% (v/v) stock, Merck) for 10min with slow agitation (neoLab® 
shaker DRS-12) in a 15ml falcon tube, spun down at 500g for 5min to settle, 
supernatant was decanted and beads were resuspended in 10ml of carbonate 
buffer for washing. This was repeated two times. The 3rd time, a 40µl beads 
sample was taken with a cut pipette tip before adding the dialysed recombinant 
Ubc9 protein and incubating the beads with the protein at room temperature for 
1h with slow agitation and then at 4°C with agitation over night. The next day, the 
beads with the bound protein were spun down, supernatant was kept on ice and 
a sample was taken up in an Eppendorf tube. Then, the beads were blocked with 
100mM Ethanolamine (Acros Organics) for 1h at room temperature with slow 
agitation to block all unoccupied coupling sites of the beads followed by 3 washes 
with 10 column volumes 500mM NaCl in 1xPBS. 
For the purification of antibodies, 9ml of crude 3rd bleed serum from an 
immunized goat from day 88 was thawed on ice and 3 aliquots of 12ml were 
generated after adjusting the overall volume to 36ml with ice cold 500mM NaCl in 
1xPBS. That was done to run several purification batches. In order to remove any 
insoluble material, the serum was ultracentrifuged at 105g at 4°C for 1h and the 
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supernatant was added to the beads. That was mixed carefully into the 15ml 
Falcon tube containing the beads and incubated at 4°C with slow agitation over 
night to bind the antibodies to the beads. 
The following day, the slurry was spun down, the supernatant was kept as further 
flow through sample, and the beads were resuspended in 10 column volumes of 
500mM NaCl in 1xPBS and subjected to a chromatography column. After 
draining of washing solution, the column was washed again with 10 column 
volumes ice cold 500mM NaCl in 1xPBS. 1ml fractions were collected by adding 
5ml of elution buffer (200mM acetic acid pH 2.7, 500mM NaCl) for two times  in 
1.5ml Eppendorf tubes, which contained 50µl of Tris-HCl pH8.0 to buffer the 
antibodies back to their native pH. Immediately after 5 fractions had been 
collected, the tubes were closed and inversed several times for mixing. For the 
rapid evaluation of the elution profile, 1µl of each fraction was spotted on a piece 
of nitrocellulose membrane and stained with 0.5% Ponceau S solution followed 
by destaining with 1% acetic acid. The fractions which contained protein were 
pooled, mixed, a sample was taken and then they were concentrated to 
approximately 500µl using protein concentrators with a MWCO of 10kDa 
(Vivaspin, Santorius). Finally the concentrated antibodies were buffer exchanged 
into 50% Glycerol (AppliChem) in 1xPBS using 2.5ml PD-10 disposable size 
exclusion columns (GE Healthcare) according to the manual and stored at -20°C. 
12.5% SDS-PAGE gels with the drawn samples were run, the antibodies in 
reducing as well as non-reducing buffer, Coomassie-stained and dried according 
to described procedures (6.5.2, 6.6.1) 
6.7.3 Characterization of affinity purified antibodies 
6.7.3.1 Specificity and sensitivity assessment by immunoblot 
The probing of 12µg Ubc9 knock down versus scrambled control cell lysates with 
the purified Ubc9 antibodies by immunoblot determined the specificity and the 
sensitivity of the antibodies. 
The knock down of Ubc9 was done applying the same ratio of siRNA to RNAimax 
reagent, as described in 6.2.3. One day before the knock down, 1x106 cells were 
seeded per 10cm dish. For the transfection, the triple amount of the transfection 
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mix and medium of a 6well (9ml) was appropriated to overcome the already 
observed and rather inefficient knock down of Ubc9 in 10cm dishes.  
The SDS-PAGE and the Western Blot were carried out as described (6.5). The 
purified goat-antibody dilutions tested were 1:1000, 1:2000, 1:4000 and 1:8000 in 
5% (w/v) non-fat dried milk/PBS 0.2% (v/v) Tween-20 and incubated at room 
temperature with agitation for 1.5h. The secondary goat-HRP antibody was used 
as described for all secondary antibodies in 6.5.3.1. 
Detection was done with ECL as well as with 20% Super-ECL to be able to 
visualize any additional nonspecific signal. 
6.7.3.2 Qualification for immunofluorescence 
In order to observe a gradually increasing expression of Ubc9, cells were fixed 
with 2% (v/v) Formaldehyde after 12h, 24h and 36h. After fixing the cells were 
overlayed with 1xPBS and stored at 4°C as long as the cultures from the last time 
point were fixed. Then, the immunofluorescence protocol described in 6.8 was 
conducted with all slides in parallel. 
For each time point one well was stained with a 1:1000 HA antibodies, one well 
was stained with 1:500 purified Ubc9-goat antibodies and a third well was stained 
with a 1:500 purified Ubc9-goat antibodies which were challenged with excess of 
recombinant Ubc9 protein prior to their use. For the challenge of antibodies,  3µl 
of the goat antibody were added to 10µl of the same recombinant Ubc9 protein 
and incubated at 22°C with 350rpm in the heating block (Eppendorf Thermomixer 
comfort) for 30min. Then, the required 1.5ml of blocking solution was added and 
mixed cautiously. The fourth well of each chamber was a secondary antibody 
control containing both antibodies used in a 1:1000 dilution. The secondary 
antibodies were both donkey-Alexa-488 (Sigma), one against mouse for the 
detection of HA, the other one against goat. Pictures were taken using the Zeiss 
Axioimager Apotome 390 (Xenon lamp power supply ebx75, Apotome power 
supply PC 167) with 6D acquisition mode in the Axiovision 4.1 imaging software. 
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6.8 Immunofluorescence 
6.8.1 Testing of histone modifications in Ubc9 knock down 
1x104 NIH 3T3 cells per well of microscopy slide chambers (Labtek) were seeded 
the day before transfection. The transfection for the knock down of Ubc9 was 
carried out as detailed in 6.2.3. 500µl of medium per well of the slide were used, 
so the siRNA-Lipofectamine complexes were mixed to the transfection medium in 
a 15ml falcon tube applying the same ratio as indicated before. The cells were 
then grown for the indicated time points and after that medium was aspirated, 
cells were washed once with ice-cold 1xPBS, fixed with 2% (v/v) formaldehyde 
(Thermo Scientific) in 1xPBS at room temperature for 10min, washed for 10min, 
permeabilized with 0.1% TritonX-100 for 5min and then washed two times with 
1xPBS for 5min. After that, cells were washed with washing solution [0.25% (w/v) 
BSA (Sigma Aldrich), 0.1% (v/v) Tween in 1xPBS] for 5min. Then the blocking 
solution (washing solution supplemented with 10% donkey serum and 2.25% 
(w/v) BSA) was added at room temperature for 30min. Furthermore, the primary 
antibody was added at the indicated dilution in blocking solution and cultures 
were kept overnight at 4°C. 
The next day, the primary antibody was incubated at room temperature for 
another 30min, and then washed with washing solution three times for 10min, the 
AlexaFluor® 488 secondary antibody (Sigma) was added fitting the species of the 
primary antibody, and slides were incubated in the dark for 1h. After that, again 4 
washes in washing solution at room temperature for 10min were performed. 
During the second wash, DAPI was added to the washing solution in a 1:1000 
dilution. Finally, wells were removed, one drop of mounting medium (DAKO) was 
applied to each preparation and cover slips (Roth) were slowly placed onto the 
stained cells starting from one side and using forceps. Then, the slides were let 
dry for approximately two hours in the dark at room temperature and in the 
following stored in the dark at 4°C. Images were taken using the Zeiss Axiovert 
390 with or without the Apotome. 
Two microscopy slides treated exactly the same as the other ones in terms of cell 
number seeded were used as a Western blot control. So cells from 1 well that 
had been transfected with the scrambled control as well as one culture treated for 
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the Ubc9 knock down were lysed in 30µl of 2x SDS-Laemmli buffer without 
bromophenol blue, 10µl of 2xSDS-Laemli buffer containing 0.2% (w/v)  
bromophenol blue and 100mM DTT were added, samples were boiled for 5min at 
95°C, spun down and separated on a 12.5% SDS gel and then blotted. For 
details refer to section 6.5. 
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7 Appendix 
7.1 List of Abbreviations 
Abbreviation Full name 
APS Ammonium Per-Sulfate 
AMP Adenosine Mono-Phosphate 
Amp Ampicillin 
ATP Adenosine Tri-Phosphosphate 
ATPase An enzyme, that converts ATP to ADP or AMP by 
hydrolysis 
CAF1 Chromatin Activating Factor 1 
CO2 Carbon Dioxide 
CpG Cystein paired to a Guanin in the same DNA strand 
DNA Di-Nucleotide-Deoxy-Ribonucleic Acid 
Dnmt1 De Novo Methyl Transferase 1 
Dnmt3a De Novo Methyl Transferase 3a 
Dnmt3b De Novo Methyl Transferase 3b 
dNTPs Mix of Deoxy-Adenosine Tri-phosphate (dATP), 
Deoxy-Guanosine Tri-phosphate (dGTP), Deoxy-
Cytidine-Tri-phosphate (dCTP), Deoxy-Thymidine Tri-
phosphate (dTTP) 
Dox Doxycycline 
DTT Dithiothreitol 
E. Coli Escherichia Coli 
EDTA Ethylene-Diamine-Tetra-acetic Acid 
EtOH Ethanol, ethyl-alcohol 
FBS Fetal Bovine Serum 
FPLC Fast Performance Liquid Chromatography 
g Gravity, 9.81m/s 
GFP Green Fluorescent Protein 
G418 Geneticin 
h hours 
H1 Histone 1 
H2a Histone 2a 
H2b Histone 2b 
H2O Water 
H3 Histone 3 
H3.3 Histone 3.3 
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H3K9 Lysine 9 of Histone 3 
H3K9me1 Mono-Methylation of Lysine 9 in Histone 3 
H3K9me2 Di-Methylation of Lysine 9 in Histone 3 
H3K9me3 Tri-Methylation of Lysine 9 in Histone 3 
H3K27 Lysine 27 of Histone 3 
H3K27me1 Mono-Methylation of Lysine 27 in Histone 3 
H3K27me2 Di-Methylation of Lysine 27 in Histone 3 
H3K27me3 Tri-Methylation of Lysine 9 in Histone 3 
H4 Histone 4 
H4K20 Lysine 20 of Histone 4 
H4K20me1 Mono-Methylation of Lysine 20 in Histone 4 
H4K20me2 Di-Methylation of Lysine 20 in Histone 4 
H4K20me3 Tri-Methylation of Lysine 20 in Histone 4 
HA Human influenza hemagglutinin 
HA-Ubc9 Human influenza hemagglutinin-Ubc9 
Hox genes Homeobox genes 
HP1 Heterochromatin protein 1 
HRP Horse Reddish Peroxidase 
ICM Inner Cell Mass 
kDa Kilo Dalton 
kb Kilobases 
LARII Luciferase Activating Reagent II 
LB medium lysogeny broth medium 
mA Milli-Ampere 
MDB1 Methyl-DNA-binding protein 1 
MEF Mouse Embryonic Fibroblasts 
min Minute(s) 
mg Milligram(s) 
ml Millilitre(s) 
mM Milli-Mol(es) 
MPa Mega-Pascal 
mQ H2O Milli-Q-water, deionized water filtered through 0.22µm 
(Millipore) 
mRNA Messanger RNA 
MWCO Molecular weight cut off 
µg Microgram(s) 
µl Microlitre(s) 
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µM Micro Mol(es) 
NaAz Sodium azide 
ng Nanogram(s) 
nm Nanometer 
NRB Non-Reducing Buffer 
Pa Pascal 
PBS Phosphate Buffered Saline 
PCR Polymerase Chain Reaction 
PML Progressive Multifocal Leukoencephalopathy 
PMSF Phenyl-Methyl-Sulfonyl Fluoride 
PRC1, PRC2 Polycomb Repressive Complex 1, 2 
RB Reducing Buffer 
rcf Relative centrifugal force 
RNA Ribonucleic Acid 
RNAi RNA interfance 
rpm Revolutions per Minute 
rRNA Ribosomal RNA 
S Sedimentation Coeffecient 
s Second(s) 
Sc Scrambled Control, mix of non-targeting siRNAs 
SDS Sodium Dodecyl Sulfate 
SDS-PAGE Sodium Dodecyl Sulfate Polyacrylamide Gel 
electrophoresis 
SIM SUMO Interaction Motif 
siRNA Small interfering RNA 
SP Sepharose Sulfopropyl Sepharose (Chemically modified beaded 
Agarose) 
SUMO Small Ubiquitin-related modifier 
TAF12 Transcription Activating Factor 12 
TAE Tris-acetic acid-EDTA 
TE buffer Tris-EDTA buffer 
TEB buffer Triton Extraction Buffer 
TEMED Tetra-Methyl-Ethylene-Diamine 
TetA Transactivator protein in the Tet-on3G system 
TRE Tet-Responsive Element 
V Volts 
°C Degree Celsius 
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7.2 Zusammenfassung 
SUMOylierung (SUMO= Small Ubiquitin-related MOdifier) ist eine post-
translationale Proteinmodifikation, welche die zellinterne Lokalisation, die Aktivität 
oder die Interaktionspartner eines Proteins verändern kann. Diese reversible 
Modifikation wurde mit vielen wichtigen zellulären Abläufen in Verbindung 
gebracht und Zahl ihrer Substrate steigt stets an. Einige Enzyme, die Chromatin 
modifizieren, werden auch von SUMO modifiziert. Viele dieser Enzyme sind für 
die Etablierung und Aufrechterhaltung von repressiver Histon- und DNA-
Methylierung verantwortlich, die charakteristisch für inaktives Heterochromatin 
sind. Die essentielle SUMO-Kaskade besteht aus drei Enzymen: einem einzigen 
E1-, einem einzigen E2- und einigen E3-Enzymen. Bei Krebserkrankungen 
wurde das E2-Enzym dereguliert vorgefunden und mit der Bildung von 
Metastasen, der Verbreitung von Tumorzellen in Geweben und mit 
Chemotherapeutika-Resistenzen assoziiert. 
In dieser Arbeit werden die Auswirkungen der Deregulierung von Ubc9 in der NIH 
3T3 Maus-Fibroblasten Zelllinie geprüft. Hierfür wurden die für an das Centromer 
angrenzendes Heterochromatin bestimmenden Histon Lysin Methylierungen 
H3K9 und K4K20 untersucht. Die dabei angewendete Ubc9-siRNA-Behandlung 
der Zellen führte zu einem Wachstumsstopp und einem Anstieg der H4K20 
Methylierung. Im Gegensatz dazu wurde keine Veränderung in der zweiten für 
diesen Abschnitt bekannten reprimierenden Histonmodifikation, der Tri-
Methylierung von H3K9, gefunden. 
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